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ABSTRACT

Presently, approximately one-third of all biopharmaceutical drugs are derived
from biological sources like gram-negative bacteria. Gram-negative bacteria like E.coli
are much cheaper to cultivate and provide higher biotherapeutic yield compared to
mammalian cells. On extracting the useful biotherapeutics from the gram-negative
bacterial cells (E.coli), endotoxin present in the bacteria is released in the surrounding
media thus contaminating the lifesaving biotherapeutics. Application of the endotoxincontaminated therapeutics to humans or animals can cause serious health issues like
septic shock, tissue injury and ultimately death. Hence, thorough purification of
biotherapeutics before parenteral application is necessary. Although there are multiple
methods for removing endotoxins, but achieving high protein recovery and purification
efficiency are still a challenge.
We have demonstrated a cost-effective technology using a biocompatible polymer
nanoparticle of approximately 800 nm diameter. The polymeric nanoparticle removed
>99% endotoxins from water, phosphate buffer saline (PBS) and protein solutions
including monoclonal antibodies (MAb). It also showed a high protein recovery of ~99
%. Additionally, the polymeric nanoparticle was capable of being reused multiple times
after being regenerated. Further, to enhance the throughput, flow properties and to scale
up the whole system, the polymeric nanoparticles were incorporated in a portable and flat
sheet biofilter. The biofilter is effective in removing >99% endotoxins from water and
protein solutions with a protein recovery of > 90%. Finally, the whole filtration set-up
being gravity driven minimized cost.
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1. INTRODUCTION

1.1. BACKGROUND
Pharmaceutical manufacturing deals with selection and optimization of the cell
source, media composition and physico-chemical bioreactor operating conditions to
maximize the culture yield and productivity (Figure 1.1) 1-3. Escherichia coli is a cost
effective and attractive choice for producing therapeutic monoclonal antibodies,
recombinant proteins and other biopharmaceuticals due to their rapid growth, minimal
nutritional requirements, high product yield and transformation capability 4-11. With the
millions of strains of bacteria, and gene-altering technology steadily improving, the
possibilities are endless 12. One of the most recognizable products derived from
genetically engineered E. coli is the hormone insulin. Before being manufactured by
bacteria, insulin was originally extracted from dogs and later pigs that was an extremely
inefficient process, making the product rare and expensive 13. The advent of E. coli produced insulin such as recombinant human insulin (Humulin) drastically increased its
availability for diabetics 14. However, biopharmaceutical products manufactured using
E. coli or other gram-negative bacteria are subject to endotoxin contamination 15-21.
Endotoxins are present in the outer cell wall of gram-negative bacteria that
contribute to the organization and stability of the membrane 16-22. Endotoxin consists of
three regions: a core polysaccharide, a long chain polysaccharide, and a non-polar lipid
called Lipid A (Figure 1.2) 20,23. The core polysaccharide has an outer hexose region and
an inner heptose region and the long chain polysaccharide is a strain-specific surface
antigen (O-antigen) that consists of repeating oligosaccharide subunits 17,20. The core
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polysaccharide and the O-antigen are both hydrophilic while Lipid A is hydrophobic. The
toxicity of endotoxin is associated with Lipid A 24-26. Lipid A triggers the production of
pro inflammatory cytokines 27,28 and activation of the coagulation cascade 20,29 which can
lead to sepsis and septic shock 30-34 . A pyrogenic reaction can be caused by as little as 1
ng of endotoxin per kilogram of body weight per hour 16-21,35. The standard unit for
endotoxin measurements is an endotoxin unit (EU), which is equal to the activity of 0.1
ng of E. coli endotoxin 36,37. For intravenous applications, a maximum of 5 EU per
kilogram of body weight can be administered to a patient per hour 36,38,39, but acceptable
concentrations in biopharmaceutical products vary depending on the required dose 40,41.
Endotoxin is highly stable and is resistant to destruction by heat or pH 25,39,42.
Additionally, endotoxins may form stable interactions with target therapeutic compounds
that further complicates separations 23,43,44. Downstream processing of recombinant
protein products accounts for approximately 45-92% of the total manufacturing costs
10,45,46

. In addition to the downstream processing, the detection of endotoxins is absolutely

critical for the safety of patients across the globe who rely on the purity of treatments
prescribed

28

. The purpose of this review is to discuss these aspects of an array of

endotoxin detection and removal technologies.

1.2. BIOLOGICAL ENDOTOXIN DETECTION TECHNIQUES
Biological detection techniques include rabbit pyrogen test (RPT), limulus
amebocyte lysate (LAL) assay and bovine whole blood assay (bWBA) that use natural
methods of endotoxin detection, and are still in use today, although they are being phased
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Figure 1.1. A simplified scheme of biopharmaceutical production, separation and
purification steps. Biopharmaceutical manufacturing is divided into two areas: upstream
fermentation or cell culture and downstream purification processes. Each area contains
multiple unit operations. The primary downstream unit operation is chromatography that
includes variations in modes such as affinity, cation-exchange, anion-exchange, ceramic
hydroxyapatite, and hydrophobic-interaction chromatography. The process performance
is mainly determined by the rate of molecule transport to the binding sites. In large
chromatographic columns, small adsorbent particles provide high surface area for binding
but generate a large pressure drop at high fluid velocity. On the other hand, large
adsorbent particles minimize active binding site per volume as well as reduce mass
transport. (Figure reproduced with permission from Jozala et. al., Ref. 3).

Figure 1.2. Schematic view of the chemical structures of endotoxin from E.coli and
properties of endotoxin binding materials.(a) Schematic view of the chemical structure of
endotoxin from E. coli. Endotoxins are lipopolysaccharides that consist of a
heteropolysaccharide (O-antigen), the core oligosaccharide, and a non-polar lipid A tail.
(b) Endotoxins form aggregates in micelle, cube, lamellar or vesicle forms exhibiting a
net negative charge in pharmaceutical solutions. The negatively charged “micellar”
endotoxins can be adsorbed on polycationic ligands, or the individual endotoxin
monomers can be removed by hydrophobic lipid tail interactions with hydrophobic
surface.
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out by newer, more accurate testing methods such as biosensors that are described after
the biological detection techniques.
1.2.1. Rabbit Pyrogen Test (RPT). The oldest and simplest of the endotoxin
detection techniques, RPT involves injecting the biological sample in question into live
rabbits and waiting for a fever to develop 23,47. This method works on the principle that
rabbits and humans share similar fever patterns under influence of endotoxins. It was
determined that a temperature increase of 0.5°C over a time span of 180 min after
injection constituted a fever 48. It was also found that it has a detection limit of
approximately 0.5 EU/ml (endotoxin unit/milliliter) or around 0.05 ng of endotoxin/ml of
solution 49. As rudimentary as the technique seems, a detection rate as low as 0.1 ng was
considered very accurate at the time of this methods development in 1912. This technique
has been praised for its accuracy; being an in vivo technique, it is easy to accept the
results of the test as researchers can physically see the test subject show symptoms of
infection. Seeing the test subject suffering the effects of endotoxins provides a
compelling argument to the presence of endotoxins in the sample. This method is often
criticized 50. The scientific world is generally moving away from live test subjects where
avoidable, in particular, animal testing. While this test was once considered the best in
the industry, and is still being performed in parts of Japan, today it is criticized for its
need for many samples, and its near-obsolete sensitivity and accuracy compared to other
methods 51.
1.2.2. Limulus Amebocyte Lysate (LAL) Assay. Unlike RPT, LAL assay
developed in the 1960s does not involve live test subjects. It does, however, rely on an
extract from the blood of the Limulus polyphemus species of horseshoe crab 52,53. The
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extract is used in one of three ways. First and simplest, the gel-clot. This test involves
mixing equal parts of extract and sample. If a gel has formed and the mixture remains
intact in the bottom of the tube, the test shows positive 54. This means the sample has at
least enough endotoxins to trigger a positive reaction, the limit of this being around the
range of 0.03 EU/mL to 0.06 EU/ml. The other two methods are turbidimetric and
chromogenic methods. Both are referred to as photometric tests as they require an optical
reader for analysis. The chromogenic assay is performed by replacing a natural substrate,
coagulen, with a chromogenic, or colored one. The chromogenic substrate is cleaved by
an endotoxin-activated enzyme coagulase, and the chromogenic molecule is released
from the substrate into the suspension measured by spectrophotometry 55. The
turbidimetric method is similar to the chromogenic method, but instead measures the
turbidity of the solution 56. The rate of turbidity and absorbance (color change) are
proportional to the endotoxin concentration. All three tests rely on the same protein,
Factor C coagulation cascade found in horseshoe crabs’ blood (Figure 3c). The endotoxin
activates Factor C which goes onto activate Factor B following the formation of a clotting
enzyme 57,58. In gel clot and turbidity assays, the clotting enzyme transforms coagulen
into coagulin, creating the gel in the gel clot test, as well as the clouding agent in the
turbidity test. The chromogenic method follows the same pathway, but instead of using
coagulen, it uses a complex of amino acids and p-nitroaniline (pNA), as the chromogenic
factor. The enzyme trims the pNA off of the complex, turning the suspension a yellow
color. This color is too faint to discern by the naked eye so a spectrometer must be used
23

. These tests are widely accepted as the official endotoxin test in the pharmaceutical

community 59. Every drug and medical device that is tested by the US Food and Drug
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Administration (FDA) must undergo and pass a LAL test 60,61. As previously mentioned,
this method is much more accurate than RPT, particularly the photometric methods. This
method still has its drawbacks. LAL assay gives both false negative and false positive
results by the presence of test interferences. False negative results are observed when
endotoxins are masked by product formulation matrices such as surfactants (e.g.,
polysorbate 20, polysorbate 80 etc.), buffer constituents (e.g., citrate, phosphate etc.) and
cell culture medium, or by aggregation with products 62-64. As a result, endotoxin is not
accessible to react with LAL reagents, a phenomenon well known as low endotoxin
recovery (LER) 65. In contrast, LAL assay also produces a falsely higher reading by the
presence of (1→3)-ß-D-glucans, a major cell membrane component that cause a false
positive reaction triggering the protease enzyme Factor G pathway and form the same
coagulin protein end product as found in LAL reactions 66,67. The LAL test is challenging
for measuring endotoxin activity in proteins, peptides and polymers because the active
site of endotoxin binds with the products neutralizing the biological activity of
endotoxins 68-71. The protein cascades the LAL assay relies on is disrupted in samples
with free metal ions, and similar to RPT, the method is subject to the same public outcry
for its treatment of horseshoe crabs. While the phlebotomy itself is not fatal, an
approximated 20% of the crabs fail to survive after being returned to sea 23. Following the
discovery of Factor C as endotoxin-activated portion of the protein cascade, attempts
have been made to replace the conventional LAL test, with one using recombinant Factor
C 72. As technology improves, alternative techniques are being developed to ease the
pressure on the horseshoe crab population.
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(a)

Figure 1.3. Endotoxin detection mechanism using LAL assay. (a) Endotoxin induced
defense mechanisms in circulating hemolymphs of horseshoe crabs. The LAL assay is
designed based on the immunogenic reactions developed in the blood of horseshoe
crabs. Upon exposure to endotoxins, the electron dense large granules (L-granule) and
less electron dense small granular (S-granule) amebocytes become activated by
zymogen factor C. (b) Coagulation cascade in horseshoe crab blood. Endotoxin
activates plasma membrane-bound factor C. Factor C is a single chain glycoprotein
(M.W. = 123 kDa) comprising of a heavy chain (M.W. = 80 kDa) and light chain
(M.W. = 43 kDa) that plays a major key role as an activator to immune system. Upon
binding with endotoxins, an autocatalytic activity triggers with the cleavage of Phe–Ile
bond resulting in an activated factor C that interacts with factor B converting it into a
clotting enzyme. Clotting enzyme cleaves coagulogen at two terminal of peptide C at
the Arg–Lys and Arg–Gly forming insoluble coagulin gel. (c) The proteolytic activity
feature of the activated clotting enzyme in horseshoe crab’s blood is used on synthetic
chromogenic i.e. Gly–Arg–p-nitroaniline substrates instead of coagulogen to detect
endotoxin as it separates p-Nitroaniline (p-NA). Upon addition of a chromogenic
substrate, Ac-Ile-Glu-Ala-Arg-pNA, the activated protease, clotting enzyme catalyzes
the release of p-nitroaniline (pNA), resulting in a yellow color that can be quantitated
by measuring the absorbance at 405 nm (or absorbance at 340 nm) and extrapolating to
a standard curve for correlating endotoxin concentrations.
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(b)

Figure 1.3. Endotoxin detection mechanism using LAL assay. (a) Endotoxin induced
defense mechanisms in circulating hemolymphs of horseshoe crabs. The LAL assay is
designed based on the immunogenic reactions developed in the blood of horseshoe
crabs. Upon exposure to endotoxins, the electron dense large granules (L-granule) and
less electron dense small granular (S-granule) amebocytes become activated by
zymogen factor C. (b) Coagulation cascade in horseshoe crab blood. Endotoxin
activates plasma membrane-bound factor C. Factor C is a single chain glycoprotein
(M.W. = 123 kDa) comprising of a heavy chain (M.W. = 80 kDa) and light chain
(M.W. = 43 kDa) that plays a major key role as an activator to immune system. Upon
binding with endotoxins, an autocatalytic activity triggers with the cleavage of Phe–Ile
bond resulting in an activated factor C that interacts with factor B converting it into a
clotting enzyme. Clotting enzyme cleaves coagulogen at two terminal of peptide C at
the Arg–Lys and Arg–Gly forming insoluble coagulin gel. (c) The proteolytic activity
feature of the activated clotting enzyme in horseshoe crab’s blood is used on synthetic
chromogenic i.e. Gly–Arg–p-nitroaniline substrates instead of coagulogen to detect
endotoxin as it separates p-Nitroaniline (p-NA). Upon addition of a chromogenic
substrate, Ac-Ile-Glu-Ala-Arg-pNA, the activated protease, clotting enzyme catalyzes
the release of p-nitroaniline (pNA), resulting in a yellow color that can be quantitated
by measuring the absorbance at 405 nm (or absorbance at 340 nm) and extrapolating to
a standard curve for correlating endotoxin concentrations (cont.).
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(c)

Figure 1.3. Endotoxin detection mechanism using LAL assay. (a) Endotoxin induced
defense mechanisms in circulating hemolymphs of horseshoe crabs. The LAL assay is
designed based on the immunogenic reactions developed in the blood of horseshoe crabs.
Upon exposure to endotoxins, the electron dense large granules (L-granule) and less
electron dense small granular (S-granule) amebocytes become activated by zymogen
factor C. (b) Coagulation cascade in horseshoe crab blood. Endotoxin activates plasma
membrane-bound factor C. Factor C is a single chain glycoprotein (M.W. = 123 kDa)
comprising of a heavy chain (M.W. = 80 kDa) and light chain (M.W. = 43 kDa) that
plays a major key role as an activator to immune system. Upon binding with endotoxins,
an autocatalytic activity triggers with the cleavage of Phe–Ile bond resulting in an
activated factor C that interacts with factor B converting it into a clotting enzyme.
Clotting enzyme cleaves coagulogen at two terminal of peptide C at the Arg–Lys and
Arg–Gly forming insoluble coagulin gel. (c) The proteolytic activity feature of the
activated clotting enzyme in horseshoe crab’s blood is used on synthetic chromogenic i.e.
Gly–Arg–p-nitroaniline substrates instead of coagulogen to detect endotoxin as it
separates p-Nitroaniline (p-NA). Upon addition of a chromogenic substrate, Ac-Ile-GluAla-Arg-pNA, the activated protease, clotting enzyme catalyzes the release of pnitroaniline (pNA), resulting in a yellow color that can be quantitated by measuring the
absorbance at 405 nm (or absorbance at 340 nm) and extrapolating to a standard curve for
correlating endotoxin concentrations (cont.).
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1.2.3. Recombinant Factor C (rFC) Assay. rFC is an endotoxin sensitive
synthetic protein that is cloned from factor C DNA to use as an alternative in vitro LAL
test 47,73-77 . In the rFC test, the binding of endotoxin activates the synthetic rFC molecule,
which then cleaves a fluorescein substrate (amino-methylcoumarin), resulting in the
generation of a fluorogenic compound. The fluorescence is measured twice, first at time
zero and then after the endotoxin has been introduced using excitation/emission of
380/440 nm. The difference in fluorescence is proportional to endotoxin concentrations in
the sample and is used to calculate a final endotoxin result. rFC is specific to endotoxin
detection eliminating the dependence on nonspecific glycan binding like that in an LAL
assay avoiding false positive results.78 The enzymatic sensitivity range to endotoxin is
0.05-500 EU/ml.73 A comparison of rFC with various LAL assays is summarized in
Table 1.1. Despite its lower limit of detection under laboratory conditions, the rFC assay
is prone to contamination in field environments that severely compromise its analytical
utility.79

Table 1.1. A comparison chart eliciting three LAL test methods: the gel clot,
turbidimetric and chromogenic method and rFC assay as available in commercial
endotoxin detection kits.
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1.2.4. Bovine Whole Blood Assay (bWBA). The test works by taking the whole
blood from the animal and introducing it to a solution containing the pharmaceutical
being tested 80. In response to endotoxin, the white blood cells in the blood produce the
cytokine Prostaglandin E2 (PGE2) in an inflammatory response, similar to that of humans
81

. The production of this cytokine is directly proportional to an increase in endotoxin

concentration. According to several studies, the test is able to accurately detect
endotoxins at concentrations of close to 0.25 EU/ml, whereas the concentration at which
humans display symptoms of endotoxin exposure typically occurs around 0.30 EU/ml 81.
This level of accuracy is very attractive for scientists looking to move away from LAL
and RPT testing. The test also is easy to perform and takes few preparational steps 23.
The storage of bovine whole blood seems to be a little less problematic than human
whole blood after 24 h of storage time at 4 °C, when the PGE 2 release is significant at
>0.16 EU/mL 81,82. The test is not without its limitations. The whole blood needed for the
tests can only be obtained from very young calves which makes it difficult to amass in
vast quantities 83. Furthermore, due to cultural and religious practices, certain countries
will not permit the collection or use of bovine blood. While its accuracy and ease of use
is admirable, it still requires animal testing, and with the advancement of technology, this
test may be replaced by other techniques.
1.2.5. Monocyte Activation Test (MAT). The Monocyte Activation Test, or
MAT, has been in development since 1995 84. The commercially available MAT kit
involves using cryopreserved monocytes in human blood to test for a reaction to
endotoxins. The response to endotoxins is determined by measurement of the induced
pro-inflammatory cytokine Interleukin – 1β (IL-1β) using enzyme-linked immunosorbent
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assay (ELISA) 85,86. The ELISA is used by attaching a primary antibody to bind with the
IL-1β released by monocytes in the presence of endotoxins, while a secondary antibody is
linked with avidin-conjugated horseradish peroxidase (Avidin-HRP) enzyme that
metabolizes tetramethylbenzidine (TMB) substrate and develops a blue-green to yellow
color product 87. The absorbance of yellow color density is then measured at 450 nm by
spectrometers, similar to a chromogenic LAL test 49. The test also has the added benefit
of testing all pyrogens and inflammatory materials that would prove harmful to human
patients 88,89. It avoids animal testing and has a detection of limit of as little as 10 EU/ml
of endotoxin solution, and conveniently, this limit becomes even smaller, and the test
becomes more accurate when using cryogenically-preserved human blood. This aids in
storage and transportation of the human blood for testing if the blood can be cooled and
preserved without sacrificing accuracy 85,90,91. The monocytes can be prepared in a
variety of ways. Some experiments have used whole human blood, while others use
monocytes harvested from leukocyte filters at blood donation centers 90. This method
displays high precision by being able to detect non-endotoxic pyrogens and their effect
on possible patients of the tested material. However, as there is often a limited supply of
human blood to be used for simply testing, inconsistencies can arise when using large
quantities of blood are used 84,92. The most important limitation for the MAT is the short
half-life (< 2 h) of viable monocytes in human blood in vitro. An alternative endotoxin
ELISA kit such as the competitive ELISA (cELISA) is available that uses a microtiter
well plate pre-coated with an anti-endotoxin primary antibody. 93 Endotoxin containing
sample or standards are added to the wells along with a fixed quantity of biotinylated
detection antibody that competes for limited binding sites on the immobilized anti-
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endotoxin antibody. Avidin-HRP conjugate and TMB are used like that in ELISA to
generate and measure color changes from blue to yellow. The absorbance reading of
coloration at 450 nm is quantitated for endotoxin concentrations present in samples.

1.3. BIOSENSOR TECHNIQUES
In attempts to modernize endotoxin detection methods, scientists have begun to
develop techniques designed around more synthetic approaches. They involve more
technology as opposed to pre-existing natural pathways. These techniques represent the
up and coming detection methods that scientists hope will eventually replace the gold
standard of RPT and LAL tests. These techniques can be split into three categories,
electrochemical, optical, and mass-based.
1.3.1. Electrochemical. The majority of electrochemical biosensors are based on
a principle called Electrochemical Impedance Spectroscopy, or EIS. Performing an EIS
requires electrodes be placed within the solution desired to be tested and delivering a
sinusoidal alternating current signal through the solution, usually ranging from 2-10 mV.
By varying the frequency of these sinusoidal waves, an impedance spectrum can be
created 94. The electrodes are coated in metal, to reduce electric resistance. Proteins that
are highly selective to endotoxin components are then bound to these electrodes such that
if the endotoxins come in contact with the electrode-protein complex, they bind to the
proteins. These proteins are referred to as Endotoxin Neutralizing Proteins, or ENPs 95,96.
When endotoxins bind to ENPs on the electrodes it increases the resistance of the
electrode. This was the case in an experiment run by Yeo et al. 97 who constructed an
electrode made of gold and a complex of human recombinant toll-like receptor 4
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(rhTLR4) and myeloid differentiation-2 (MD-2) proteins (Figure 1.4). They exposed
these electrodes to solutions of varying endotoxin concentrations and created impedance
spectrums for each of these concentrations. The maximum current across all potential
differences was lower at higher concentrations of endotoxin 86. The study also reports that
this particular biosensor has high specificity towards endotoxins, in order to prevent false
positive results. It then goes on to state that the sensor had a detection limit of 0.0002
EU/ml. This is drastically lower than the standard LAL test limit of 0.03 EU/ml. A major
limitation of this system is the single time use of electrodes once endotoxins are bound to
TLR4-MD-2 complexes. Metal complexes immobilized upon a gold electrode have been
used and were able to detect endotoxins at concentrations as low as 0.001 EU/ml

98

.

Porous silicon membranes (pSim) based electrochemical biosensors comprise of array of
nano-channels which are modified using Polymyxin-B, with strong affinity to endotoxins.
It shows the limit of detection of 18 EU/ml. These sensors showed ability to detect
endotoxins from various bacterial strains like E. coli and S. typhimurium and all this is
done in a label free manner 99. Studies have also reported highly sensitive peptide
modified gold electrode based electrochemical biosensors which are used for endotoxin
detection with very low limit of detection of 0.04 EU/ml 100. These methods are faster,
more accurate, and in most cases, more cost effective than biological based techniques
101

. Two other electrochemical techniques are amperometric and potentiometric methods.

Amperometric transducers have been described as the most common of the
electrochemical sensors used for endotoxin detection 102. They work on the relying on the
same principle of EIS, wherein the concentration of the analyzed sample has a linear
relationship with the current measured. This method is able to use premade, disposable
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testing strips, for fast, cost-efficient testing 103. Potentiometric methods are worth noting
because although their detection limits are relatively high, 1-5 EU/mL, they were the first
biosensor to be able to detect endotoxins in real time 94,104. The methods in which the
electrodes are created, as well as the ways in which they are measured and utilized, are
more complicated and labor-intensive than the biological methods 105. They require more
sophisticated personnel and equipment to be run effectively than RPT or LAL tests 106.

Figure 1.4. A new electrochemical endotoxin sensor. (A) and (B) The design and
fabrication of a new electrochemical endotoxin sensor based on a human recombinant
toll-like receptor 4 (rhTLR4) and myeloid differentiation-2 (MD-2) complex. The
rhTLR4/MD-2 complex, which specifically binds to endotoxin, was immobilized on gold
electrodes through a self-assembled monolayer (SAM) technique involving the use of
dithiobis (succinimidyl undecanoate) (DSU). (C) – (F) The electrochemical signals
generated from interactions between the rhTLR4/MD-2 complex and the endotoxin were
characterized by cyclic voltammetry (CV) and differential pulse voltammetry (DPV). (G)
A linear relationship between the peak current and endotoxin concentration was obtained
in the range of 0.0005 to 5 EU/mL with a correlation coefficient (R2) of 0.978. The
estimated limit of detection (LOD) was fairly low, 0.0002 EU/ml. The rhTLR4/MD-2
based sensors exhibited no current responses to dipalmitoylphosphatidylcholine (DPPC)
bearing two lipid chains, which is structurally similar to endotoxin, indicating the high
specificity of the sensors to endotoxin. Reproduced with permission from Ref. 78.
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1.3.2. Optical Techniques. One such example is that of liquid crystal (LC) based
optical sensor for highly sensitive endotoxin detection. LC based optical biosensors are
developed using endotoxin specific single-stranded DNA aptamers which are the
endotoxin selective probes of the biosensors. The LC based aptamer optical biosensors
have linear endotoxin detection range from 0.05 to 1000 EU/ml and a detection limit of
5.5 EU/ml. The biosensors have negligible cross-binding reactivity with the biomolecules
thus maximizing their recovery 107. Broadly, these optical techniques can be divided into
three distinct categories: luminescence, Surface Plasmon Resonance, and
electrochemiluminescence that share the similar characteristic of relying on visual
changes.
1.3.3. Fluorescence and Luminescence Techniques. The bioluminescence

method is based on the same principle of the LAL assay except the end point material
(pNA) of LAL tests is used as the starting material for the mutant firefly luciferase 108,109.
Luciferin-modified pNA has been designed as the substrate for a mutated version of the
North American luciferase (Photinus pyralis) that can quickly and precisely identify
solutions containing endotoxins by a bioluminescence reaction 109. The reaction generates
high luminescence intensity and shows a luminescence 10 times as intense as the
standard, wild-type luciferase 110. The lowest endotoxin concentration recorded was
0.0001 EU/mL, while the researchers report a detection limit of this mutant-type
luciferase bioluminescence technique was 0.0005 EU/ml 23. Another important factor to
mention is that this detection limit was reported in 15 minutes. This required time is rapid
in comparison to the LAL gel-clot techniques estimated required time of 138 minutes to
nearly 1.5 hours 111. Experiments have been performed using a peptide biosensor and
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attached fluorescent probes, fluorescein-maleimide (F5M), and tetramethylrhodamine-5malemide (TMR5M) 85. Recently, a fluorophore BODIPY ((4,4-Difluoro-1,3,5,7,8Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene) with excitation and emission wavelengths
of 485/20 and 528/20 nm were used to quantify presence and removal of endotoxin from
biological solutions (Figure 1.5) 112-115. BODIPY dye which is a lipid biomarker, in
presence of endotoxin quenches due to endotoxin binding to its surface signaling
endotoxin contamination 112,113,116. The difference in the fluorescence of BODIPY which
indicates the degree of quenching of the dye is plotted against the amount of
corresponding endotoxin to generate standard curves. Endotoxin detection studies have
been conducted using Alexa Fluor-labeled fluorescent endotoxin with excitation and
emission wavelengths of 490 and 525 nm 117. In this study, C-18 acyl chain modified
Fe3O4/Au/Fe3O4 nanoflowers were used for simultaneous capture and detection of
endotoxins from water samples 117. The lowest endotoxin detection limit that was tested
using this technique was 10 EU/ml 117.

Figure 1.5. Fluorescent assay protocol for endotoxin detection. We have developed a
fluorescence-based method that measures the changes in fluorescence intensity and the
corresponding endotoxin concentration. The whole process is instantaneous and can
detect endotoxin as low as 0.0001 ng/ml in solutions.
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1.3.4. Surface Plasmon Resonance (SPR) and Mass-based Techniques. Zhang
et al. have shown a smartphone biosensor platform using SPR. The disposable sensor
chip utilizes the smartphone’s built in flash as a light source and a compact diffraction
grating and spectra dispersive unit 118, but this technology is still in development. Recent
publication regarding antibiotic mediated plasmonic biosensors for endotoxin detection
have shown a low limit of detection of 40 EU/ml 119. The plasmonic biosensor is based
on a facile U-bent fiber optic probe (UFOP) technology that utilizes
octadecyltrichlorosilanes (OTS) on the surface of optical fiber probes to hydrophobically
entrap endotoxin from aqueous solutions. The binding of endotoxins has been monitored
in real-time by measuring the change in refractive index (RI) in the evanescent layer 119.
To add specificity and signal amplification, the bound endotoxins have been further
tagged with antimicrobial polymyxin-B conjugated gold nanoparticles (PMB-AuNPs) in
a sandwich format. The resulting evanescent wave absorbance-based fiber optic
biosensor has excellent sensitivity with the total assay time of 1 h 119.
An example of mass-based techniques is electromagnetic piezoelectric acoustic
sensors, or EMPAS that has been touted as being able to measure multiple types of
pathogens, not exclusively endotoxins, as well as being able to detect endotoxins in real
time within human blood plasma 120. EMPAS uses ultra-high frequency acoustic wave
sensing based on an ultrathin, oligoethylene glycol-based mixed surface platform coated
on piezoelectric quartz discs. The glycol end on the surface of quartz has been
functionalized with polymyxin B (PMB), a cyclic peptide antibiotic that shows high
affinity for endotoxins and hence, has been used as the biosensor assay for endotoxin
detection. Incubation of endotoxin-spiked whole blood with PMB-bead chemistry
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resulted in the EMPAS resonant frequency shift (f) as a function of endotoxin
concentration from 30-60 EU/ml 120. Another mass-based method is magnetoelasticity
that function by placing sensors directly on to dry testing surfaces, such as medical
equipment or food. The sensor filaments, whose oscillation frequencies are monitored,
fluctuate within a magnetic field. These sensors are coated in phages designed to bind
with the target pathogen, like ENPs 121. When Salmonella typhimurium bind with the
surface of sensors, the mass of sensor increases, resulting in a decrease in the sensor’s
resonant frequency. The resonant frequency of the sensors has been measured wirelessly
and compared with their initial resonant frequency. Control sensors without phage do not
show any shifts in the resonance frequency and have been used to compensate for
environmental effects and nonspecific binding 121. The resonant frequency change of
sample measurement sensors has been reported to be statistically different from that of
control sensors down to 5102 colony forming unit/ml, the detection limit for the work.
The number of cells bound on the sensor surface have been imaged using scanning
electron microscopy (SEM) that has been further verified the measured resonant
frequency changes due to cell binding on the sensor surface. The total assay time of the
presented methodology has been reported approximately 30 min. While the
disadvantages of phage coated magnetoelastic sensor are non-regeneration of the surface,
non-specificity and interferences from analytes, it may be advantageous as a disposable
sensor due to low cost.
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1.4. TECHNIQUES FOR DOWNSTREAM REMOVAL OF ENDOTOXINS
Downstream process for pharmaceutical manufacturing comprises of three steps:
(1) initial recovery by extraction or isolation, (2) purification and (3) polishing 1-3.
Endotoxin removal presents a unique challenge, which form stable interactions with
themselves and possibly with target therapeutics.
1.4.1. Ultrafiltration. A single endotoxin molecule in its monomeric form has a
molecular weight 10-30 kDa 22 depending on the core polysaccharides and
oligosaccharide chain, but endotoxins have the ability to aggregate and form micelles and
vesicles with molecular weights above 1000 kDa 29 and diameters up to 0.1 μm 20. The
endotoxin micelles and vesicles can be separated from water, salts, and small target
therapeutic molecules through size exclusion in ultrafiltration. Factors that affect the
removal of endotoxins from aqueous solutions include the size distribution of the
molecules in solution, the interactions between target molecules and endotoxin,
therapeutic protein concentration and the presence of detergents. The effect of protein
concentration on the endotoxin removal efficiency using ultrafiltration membranes has
been explored 22,122. Ultrafiltration membranes with 100 kDa molecular weight cut off
(MWCO) has been used to filter endotoxin contaminated protein solutions with
concentrations varying between 2-30 mg/ml. The % endotoxin removal in the filtration
permeate through the membrane ranges from 28.9% to 99.8%, depending on the level of
protein concentration and endotoxin dilution 22. The more dilute the protein samples are
made, the higher is the rate of endotoxin removal due to the shift in equilibrium from
endotoxin aggregates into monomers in dilute solutions and passing endotoxin monomers
through the membrane.
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Effects of detergent concentrations on the interactions between endotoxin
molecules have been studied contributing towards efficient endotoxin removal. Multiple
Tween 20 concentrations of 0.0%, 0.5%, 1.0%, and 2.0% have been added to the protein
solutions to calculate the respective removal efficiency 22. An increase in the Tween 20
concentration has led to an increase in the passage of endotoxin into the permeate and
thus removing endotoxin from proteins 22. These results demonstrate that the presence of
a detergents decreases the size distribution of endotoxin aggregates. As the detergent
concentration has been increased, the equilibrium has shifted from micelles and vesicles
to monomers 22,122. This method is undesirable for ultrafiltration where endotoxin
monomers are to be trapped within the membrane and desired protein be allowed to pass
as they are less likely to be stopped by the filtration membrane compared to endotoxin
aggregates.
Ultrafiltration has been used to separate endotoxin molecules from small target
therapeutic drug molecules. For example, ultrafiltration has been utilized to separate
endotoxin aggregates from BMS-753493, a small aqueous drug molecule with a
molecular weight of 1.57 kDa 123. Two membrane sizes have been used to perform
endotoxin decontamination of the drug molecules: 3 kDa and 10 kDa. The product
permeates through the membrane while endotoxins are retained on the membrane. Both
ultrafiltration membranes are effective in reducing the endotoxin concentration to below
0.03 EU/mg but compared to the MWCO of 3 kDa, the 10 MWCO has higher drug yield
of around 95% unlike the 3 kDa membrane which shows around 55% loss of the desired
product

123

. Thus, ultrafiltration membranes are an effective tool for removing

endotoxins from aqueous drug molecules and other therapeutic products 123.
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The main limitation associated with the ultrafiltration technique is that in most
cases it can be used to remove endotoxins from molecules that are magnitudes smaller
than endotoxin aggregates. For this reason, this method is not applicable for most
endotoxin separation scenarios. Ultrafiltration is best suited for removing endotoxin from
water, salts, or small molecule therapeutics that do not have an affinity for endotoxin .
1.4.2. Extraction. Solvent extraction is used to separate endotoxins from target
therapeutics based on their relative solubilities in two immiscible liquids. Endotoxins
form partition in the organic phase, while hydrophilic target molecules remain in the
aqueous phase. Endotoxins have been effectively removed from the bacteriophages T4,
HAP1, and F8 using 1-octanol with endotoxin removal efficiencies varying between 64 99.9%. 36. Additional processing is required to remove any trace quantities of 1-octanol
present in the aqueous phase as the presence of 1-octanol interferes with the LAL test for
endotoxin detection 36. Even though solvent extraction technique gives high endotoxin
removal from various therapeutics solutions, the product yield is significantly low and
varies between 30-60% impacting the profits associated with the method where it may
not be a practical choice for this application 36.
Two-phase extraction using detergent Triton X-114, a non-ionic surfactant
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, has

been explored to remove endotoxins from target therapeutics. Endotoxin was successfully
removed from the green fluorescent protein using Triton X-114 and temperature
transitions. Triton X-114 is miscible with water at a temperature of 0°C, but a phase
separation occurs at temperatures above 23°C 125. Endotoxins are partitioned in the
detergent phase while the target therapeutics are partitioned in the aqueous phase.
Endotoxin removal efficiencies using Triton X-114 ranged between 45-99% 125. In
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addition to high endotoxin removal, Triton X-114 results in high product recovery of over
80% 16.Triton X-114 isothermal extraction using sodium dodecyl sulfate (SDS) has also
been very effective in removing endotoxins from pDNA with residual endotoxin
concentration of around 16 EU/mg. Moreover, using this extraction technique, a pDNA
recovery of over 80% was reported. While isothermal extraction was proven effective for
plasmid-endotoxin removal, this method is not applicable for the removal of endotoxins
from protein solutions because SDS completely denatures proteins causing significant
changes to protein conformation 126. One major disadvantage of temperature transition
extraction using Triton X-114 is that the repeated heating and cooling degrades
therapeutic products 126. Extraction processes provide a rapid separation that is easily
scalable and can achieve high removal efficiencies, especially with high initial
concentrations 36,125,127. However, final endotoxin concentrations in the aqueous phase for
both solvent extraction and Triton X-114 extraction remained above desired
specifications, meaning additional processing is required .
1.4.3. Ion Exchange Chromatography. Anion exchange chromatography can be
used to separate negatively charged endotoxin molecules from positively charged
molecules, such as basic proteins. Proteins exhibit different charges at different pHs. A
protein exhibits a neutral charge if the pH is equal to its isoelectric point (pI), a negative
charge if the pH is > its pI, and a positive charge if the pH is < its pI 128. The pI of an
endotoxin molecule is ~2 16,20,129, meaning endotoxins are negatively charged under
conditions typically encountered during chromatography. At pH < 2, the target protein
exhibits a net positive charge and is repelled by a positive stationary phase while the
negatively charged endotoxins interact with the stationary phase and leaves the column at
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a lower velocity 130,131. Anion exchange chromatography is not ideal for removing
endotoxins from negatively charged target molecules, such as pDNA or acidic proteins
132,133

.
If significant ionic interactions are present between target proteins and endotoxins

or between the protein and the resin, a decrease in protein yield or an insufficient
separation may be observed. If the protein and the endotoxin have a strong interaction,
endotoxins leave the column bound to the target protein. If there is a strong attractive
interaction between the target protein and the resin, the protein yield is low 129.
To lessen undesirable interactions, the pH of the protein solution is adjusted. The
effects of resin volume and contact time in addition to pH and conductivity on the
efficiencies of endotoxin removal have been explored for therapeutic products like,
antigens NY-ESO-1, Melan-A, and SSX-2 129. The pIs of these antigens were 9.1, 8.7,
and 6.2, respectively. NY-ESO-1 and Melan-A are both hydrophobic molecules while
SSX-2 is hydrophilic 129. All tests were run using equilibrated Q XL resin. An increase in
resin volume and endotoxin-resin contact time had a positive effect on endotoxin removal
and the concentration of endotoxins in the permeate consistently decreased with increase
in above variables. Low endotoxin concentration of ~ 0.4 EU/µg was obtained in the
permeate and a protein recovery of > 80 % was obtained consistently at almost all resin
volumes 129. While positively charged proteins are less likely to interact with the resin and
remain in the column, they may also demonstrate an undesirable attraction to endotoxins.
To minimize protein- endotoxin interactions, the pH chosen should be high enough to
avoid giving the protein a strong positive charge. Effect of different pHs on the removal
of endotoxin from protein Melan-A, a hydrophobic protein with a pI of 8.7 has been
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studied. Melan-A exhibited a strong ionic interaction with endotoxins below its pI,
causing endotoxins to leave the column with the target protein. To remedy this, the pH
was increased to weaken such interactions 129. The pH tested were 7.9, 8.4, 8.9, and 9.2,
which corresponded to endotoxin concentrations in the permeate of 1.4, 1.8, 0.6, and 0.5
EU/µg 129. As the pH was increased above the protein's pI, the endotoxin concentration
decreased dramatically and with no significant impact on the protein yield 129.
The success of ion-exchange chromatography is highly dependent on the target
molecule, but in general ion-exchange chromatography can achieve an endotoxin
reduction of five orders of magnitude for concentrated solutions (>1,000 EU/ml) or three
to four orders of magnitude from dilute endotoxin solutions (<100 EU/ml) 20. The resin
involved with an ion exchanger can be regenerated by washing with detergents to
separate endotoxins from the resin surface and additional washing steps 134.
1.4.4. Affinity Chromatography. Affinity chromatography is used to separate
endotoxins from target molecules using highly specific interactions between endotoxins
and a ligand bound to a stationary phase 135. Because of the specificity of the ligand, there
is little to no product loss during separation 35. The target therapeutic molecule will elute
with a greater velocity than endotoxin molecules due to specificity. The ligand chosen
should have a strong interaction with endotoxins and a weak interaction with the target
therapeutic molecule at separation conditions. Affinity chromatography is applicable to a
wide range of target molecules, including proteins and pDNA 136,137.
It is important to note that the exact structure of endotoxins varies between
bacteria strains based on the core polysaccharides and the long chain polysaccharide. For
this reason, ligands are typically designed to interact 20 with the most conserved section
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23,25,29,138

of the endotoxin molecule, Lipid A , through hydrophobic 129 and electrostatic

interactions 20. Common ligands used in affinity chromatography include PMB, histidine,
dimethylamine ligands, deoxycholic acid and polycationic ligands 17,139. Hydrophobic
polymers in the form of nanoparticles have been explored for removing endotoxins from
water and protein solutions.112,113
One of the most commonly used ligands is PMB, a cyclic lipopeptide with a high
affinity for endotoxin (Figure 1.6). As a ligand, PMB induces the dissociation of
endotoxin aggregates 140 and binds to the Lipid A section of endotoxins 141 through
hydrophobic interactions 142. PMB’s affinity to endotoxin can be attributed to the
terminal amidine groups that are spaced such that interactions between amidine groups
and the two phosphate groups on Lipid A can occur simultaneously 143. In addition to
being used as a ligand, PMB is an antibiotic used to treat gram-negative bacterial
infections. Despite PMB’s high affinity for endotoxin, columns utilizing PMB may
experience a higher than average product loss 20. This is because there are positive
charges on the amino acid groups on PMB that may attract negatively charged target
molecules. Additionally, PMB is both neurotoxic and nephrotoxic, which may cause a
problem if the ligand is released from the column 25. Work has been going on to develop
peptides with similar compositions to PMB but with a decreased toxicity. These peptide
analogs displayed a strong affinity to endotoxin as well as a decreased lethality when
introduced intravenously into mice 144.
The nitrogenous bases adenine, cytosine, histidine and histamine all display an
affinity for endotoxin. Of these, histamine and histidine are equally as effective as
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Figure 1.6. Chemical structures of various endotoxin binding ligands. Since endotoxins
are negatively charged, anion exchange ligands are employed, e.g., diethylaminoethane
(DEAE), polymyxin B, histamine, histadine, poly-l-lysine, polyethylimine (pEI) and
chitosan.

polymyxin B and have been successful with separating endotoxin molecules from
albumin, insulin, lysozyme, myoglobin, and others. Although histamine and histidine are
considered equally effective, histamine is biologically active and may create
immunogenic response in the body 20. On the other hand, histidine may work well for
small sample volumes with a limited reduction of endotoxins, however, at the expense of
large sample volumes, product losses cause low yield 20,138. Deoxycholic acid (DOC) is
another ligand option that may offer a higher product recovery due to a low charge
density that reduces ionic interactions with negatively charged proteins 20. While
recombinant protein purification is primarily based on the use of tags, tag-free
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alternatives have emerged as a convenient and popular approach because of less
processing time. Such an example is the purification of PspA4Pro protein with one step
by washing contaminant proteins using a cationic detergent, cetyltrimethylammonium
bromide (CTAB) and centrifugation to remove endotoxins in aggregates, or, cryoprecipitation of contaminants in the precipitate and recovery of PspA4Pro protein in the
supernatant 145. Comparison of CTAB wash and cryo-precipitation with ion-exchange
chromatography shows higher protein recovery (~92%) and intermediate recovery
(47.8%) in CTAB and cryo-precipitation, respectively than 35-62% using
chromatography 145. The % endotoxin removal were 96.5%, 99.9% and 99.5-99.9% for
CTAB, cryo-precipitation and chromatography, respectively 145. This new strategy
enables does not require the use of affinity tags, thus reducing the overall costs of protein
purification.
Cost effective ligand and its binding capacity are key factors for endotoxin
removal in a purification process. Poly--lysine and polymyxin-B are two commonly
used ligands in protein purification. Table 1.2 provides a reference list of these ligands
with regards to endotoxin binding capacity, protein recovery, regenerability and cost that
are commercially available for use in several different product names 112,113,115,146-151.
Additionally, the contact time required between the solution and ligand will affect the
cost. A process with a high contact time will required a larger column and therefore a
greater initial investment.
The pore size of the resin should also be considered. A small pore size will
increase the retention of endotoxin in the column by size exclusion, while larger pore
sizes will reduce the ionic interactions with anionic proteins 20. Studies have been
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Table 1.2. Commonly used affinity-based ligands for endotoxin removal in
chromatography.
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conducted to study the effect of pH and ionic strength solutions on endotoxin removal
efficiencies from hemoglobin samples using an Acticlean Etox affinity column.
Endotoxins have been reported to form stable complexes with hemoglobin, thus
complicating separation 43,152.The effect of ionic strength on endotoxin removal
efficiency and hemoglobin recovery have been studied using two different salt solutions
(NaCl and CaCl2). The endotoxin removal efficiency displayed a decreasing trend as the
ionic strength was increased. However, the endotoxin removal efficiency for CaCl 2
solutions displayed a more drastic initial decrease than that for NaCl solutions. These
results indicate that not only do ionic interactions play a role in affinity chromatography,
but the types of cations matter as well 43.
Unlike the endotoxin removal efficiency, the ionic strength and cation type had a
limited effect on the product recovery from hemoglobin-endotoxin solutions. For all
endotoxin contaminated hemoglobin solutions tested, the recovery of hemoglobin showed
an increasing trend as the ionic strength was increased. Beyond, the ionic strength of 0.10
M, the hemoglobin recoveries remained relatively constant or displayed a gradual
decrease with values over 95%. Though there existed interactions between endotoxins
and hemoglobin that hindered separation but all the endotoxin contaminated hemoglobin
solutions prepared with either NaCl or CaCl 2 had hemoglobin recoveries above 99% for
ionic strengths of 0.1 M, indicating that there is both an attraction between hemoglobin
and the affinity resin and between hemoglobin and endotoxin which are weakened at an
ionic strength of 0.1 M 43.
The effect of pH on endotoxin removal efficiency and hemoglobin recovery was
tested using different buffer solutions. The endotoxin removal efficiency of resins was
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governed by the pI. There was a continuous and gradual decrease in endotoxin removal
efficiency as the pH was increased from 4.5 to 8, and then the removal efficiency
plummeted when the pH was increased from 8 to 9 because the pI of the affinity resin
was 8. As the pH was increased from 4.5 to 8, the resin became less positively charged
and was therefore less effective at attracting negatively charged endotoxins through
electrostatic interactions but other affinity mechanisms were still present. As the pH was
increased beyond 8, the resin moved from having a neutral charge to a negative charge
that repelled endotoxins and overpowered some of the attractive affinity interactions. On
the other hand, the pH or pI had a minimal effect on hemoglobin recovery; the recovery
of hemoglobin from endotoxin solutions was above 97% for all pHs tested

43,143

.

Commercial resins employing hydrophobic and/or cationic ligands to remove
endotoxin from proteins and biological solutions use porous nano and/or microparticles
and have shown great promise in protein purification, but the type of ligand immobilized
or incorporated within the matrix still governs its intravenous application. Many of these
resins have shown reasonable endotoxin binding efficiency from therapeutic proteins and
biological solutions but suffer from major shortcomings like low recombinant protein
recovery and difficulty in intravenous application due to nephrotoxicity and neurotoxicity
associated with the endotoxin binding ligands. Toxicity related shortcoming can surely be
addressed by using biocompatible endotoxin selective polymers which are non-toxic.
Another major concern associated with most of the porous resins used for endotoxin
removal is that they come in packed bed form which suffer from major drawbacks like
high pressure drop (due to combined effect of bed consolidation and column blinding)
and poor mass transfer (as intraparticle diffusion is responsible for transport of solute to
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the binding sites), thus making their application expensive and adding significant cost to
downstream purification.
The toxicity, pressure drop and mass transfer related shortcomings were
addressed by using biocompatible, rigid and non-porous particles where adsorption takes
place on the surface. One such study focused on using biocompatible and environment
friendly polymer, poly--caprolactone (PCL) nanoparticles ~ 800 nm to remove
endotoxins from water and protein solutions 112,113. The PCL nanoparticles (PolyBalls)
were non-porous in nature and thus the endotoxin binding took place on the surface of the
particles (Figure 1.7 (a)). PolyBalls showed high endotoxin removal efficiency of >99%
from phosphate buffer saline (PBS) solution. These particles were also effective in
removing endotoxin from protein solution prepared in water with more than 90% removal
efficiency 112. The removal efficiency was >99% when protein solutions were prepared in
phosphate buffer saline (PBS) 112. The research also reported high endotoxin binding
capacity of ~ 1.5 × 10 endotoxin unit (EU) per mg of particles 112. In addition to high
endotoxin removal the particles offered high protein recovery in excess of 90% thus
maximizing therapeutic product recovery. High endotoxin removal in presence of PBS
was attributed to the creation of shielding effect in presence of lyotropic sodium chloride
salt. Considering larger-scale industry applications, combinatorial techniques were
applied to construct PolyBall containing flexible and multifunctional biofilters (Figures
1.7 and 1.8). Contaminated samples were allowed to flow from one side of the filter to
the other. The kinetics of endotoxin removal efficiency were determined as a function of
concentration that also removed >99% endotoxins from water.
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Figure 1.7. PolyBall nanoparticles based effective endotoxin removal. (a) PolyBall
nanoparticles are synthesized using the solvent diffusion method. (b) PolyBalls can be
lyophilized in white powder form and stored at room temperature (~22 °C). (c) PolyBalls
are effective in removing >99% endotoxins (> 2x106 EU/ml) from water (dotted line) and
PBS (pH 7.4) (solid line). Change in LPS concentrations does not compromise PolyBall’s
endotoxin removal efficiency. (d) PolyBalls efficiently remove endotoxins from a variety
of protein solutions at different concentrations. (e) Removal of endotoxins does not affect
protein recovery (>95% recovery) indicating minimal product loss and PolyBall’s
specificity towards endotoxins even in endotoxin mixed protein solutions. (f) PolyBalls
can be regenerated to remove endotoxins further. Figures reproduced with permission
from Ref. 97 (Razdan et. al.).

One major advantage of the biocompatible PolyBalls and multifunctional
biofilters is that they can be reused for endotoxin binding quite effectively without a
major loss in binding efficiency. PolyBalls can be regenerated by breaking endotoxin-
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nanoparticle complexes which makes the endotoxin removal process more efficient and
scalable.

Figure 1.8. PolyBall nanoparticles incorporated cellulose acetate (CA) membrane for
effective endotoxin removal. (a) PolyBall nanoparticles are embedded in a cellulose
acetate (CA) biofilter. (b) Cross-sectional view of a CA filter without any nanoparticles
(negative control) using SEM. (c) SEM image of a biofilter with PCL nanoparticles
impregnated in it. (d) Our biofilter removes >99% endotoxins (solid line) while filter
without PCL nanoparticles (negative control) is not as effective as the biofilter in
removing endotoxins indicating the role of PCL nanoparticles in binding and removing
endotoxins from solutions. (e) Comparison of the endotoxin removal efficiency (solid
line) and protein recovery (dotted line) between our filter and other commercial
endotoxin removal filters. Our filter outperforms others while removing >99%
endotoxins and maintaining >95% protein recovery. Figure reproduced with permission
from Ref. 97 (Razdan et. al.).
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Figure 1.8 (e) and Table 3 showcase a comparison of different endotoxin removal
products in terms of binding capacity, protein recovery and cost. Although, non-porous
particles solve the mass transfer related limitation but the problem of high pressure drop
during purification operation still persists. Due to the specificity of the ligand, affinity
interactions offer a low product loss with a wide range of applications. Both mixed-mode
chromatography and membrane adsorption use similar mechanisms and experience
benefits.

Table 1.3. Comparison of endotoxin removal products, their adsorption capacity, costs
and regenerability.
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1.4.5. Mixed-Mode Chromatography. Mixed-mode chromatography is a
growing separation technique in the biopharmaceutical industry 45,153,154. While
traditional chromatographic methods rely on a single dominant interaction between the
ligand and the targeted molecule, mixed-mode chromatography (MMC) utilizes multiple
interaction modes for an increased separation 45,154,155. When compared to traditional
chromatographic methods, MMC offers an increased retention and selectivity of the
targeted compound 156,157, especially for polar charged molecules 153,154. Many ligands
used in affinity chromatography, such as histamine and histidine can be considered
mixed-mode ligands due to their beneficial secondary interactions 133,157-159.
1.4.6. Membrane Adsorption. Membrane adsorption exploits the same
mechanisms used in affinity and ion-exchange chromatography, but offers a reduced
processing time and initial investment. Similar to affinity chromatography, a product
yield near 100% can be achieved 35,160. In membrane adsorption, the same ligands used in
affinity chromatography or resins used in ion-exchange chromatography are bound to a
support medium. The use of a membrane greatly improves flow rates and nearly
eliminates diffusion limitations. Membranes can be made of nylon, PVA, PEVA, PVDF,
cellulose acetate and cellulose 25,112,160. The membrane capsules are single-use, meaning
there is no need for eluting, cleaning, or regenerating. Benefits of single-use membranes
include a decreased chance of product contamination as well as a decreased process time
and buffer volume due to the decrease in required cleaning steps 38. Membrane adsorption
requires a low initial investment when compared to traditional chromatographic methods,
but membranes must be continually purchased, which will affect manufacturing costs 38.
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In the past, membrane adsorbers have not been widely adopted because it had a
lower binding capacity than that of traditional chromatography methods. Endotoxin
removal efficiencies of histidine immobilized on a nylon membrane for different
endotoxin concentrations have been carried out. The ligand density for the membrane
adsorbers studied was 7.38 mg/g. As the initial endotoxin concentration was increased,
the removal efficiency was greatly decreased. This demonstrates the limited binding
capacity using membrane adsorbers. Even at the lowest endotoxin concentration of 387
EU/ml, the removal efficiency was only 65% 25. These results are consistent with those
from previous studies that saw endotoxin removal efficiencies of approximately 70%
with an initial endotoxin concentration of 6,000 EU/mL 161. Recently, membrane
adsorbers with high efficiency endotoxin removal and binding have been synthesized.
One such example of membrane adsorbers is that of amphiphilic carbonaceous particles
(ACPs) incorporated in the polyvinylidene fluoride (PVDF) matrix. The absorbers have
been successful at removing endotoxins from BSA protein solutions at >99.8% efficiency
with >90 % protein recovery.160 Another study with PCL nanoparticle incorporated in the
cellulose acetate membranes have been able to effectively remove endotoxins from water.
The endotoxin binding capacity offered by the membrane adsorber was ~ 2.7 × 10 EU
per mg particle compared to endotoxin binding capacity of ~ 1.4 × 10 EU per mg
particle offered by PCL nanoparticles in suspension 112.

1.5. DISCUSSION
The biopharmaceuticals industry has experienced a rapid and consistent growth
over the past few years 162-165. It is predicted that half of all drugs under development will
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be biopharmaceuticals within the next 5-10 years 3. Developing endotoxin removal
methods that are both effective and cost efficient is an ongoing challenge 45 due to the
high purity required and the potential interactions present between endotoxin and target
molecules. Affinity and mixed-mode chromatography are the most promising methods
for a widely applicable removal method due to the highly selective interactions between
endotoxins and the chosen ligand. Additional research is still required to further develop
additional methods for removal and ligands that demonstrate a high affinity to endotoxins
with a low toxicity and cost. There is also ongoing research to develop endotoxin-free E.
coli strains that would eliminate the need for endotoxin removal and decrease
downstream processing costs 10,166,167. Another development is the use of alternative
expression systems other than E. coli such as mammalian cell lines (e.g., Chinese hamster
ovary and human embryonic kidney 293) or engineered yeasts 168. However, endotoxin
contamination may originate from other sources such as additives, buffers, cell culture
medium, reagents, serum, supplements and water 169. Therefore, biomanufacturing
processes focus on developing innovative and effective technologies for in-line endotoxin
detection sensors and removal of endotoxins and other contaminants from process
solutions.
Biological techniques led the way, starting with the RPT, a crude, yet effective
method of testing medicines before injecting them into humans. This was a good start,
but with a detection limit of 0.5 EU/ml, and taking over two hours to perform, as well as
requiring live rabbits for test subjects, it was quickly outclassed by other methods.
Following close behind RPT, was LAL assay testing. The LAL assay became the
industry standard in medicine and equipment testing 170. A number of parental
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pharmaceutical products such as Ampicillin, Cytarabine, Diclofenac, Dexamethasone,
Heparin, Insulin, Gentamicin, Glucose, Saline solution, Vaccine, Vitamin, plasmid DNA,
proteins etc. are routinely screened for endotoxin detection using LAL tests 171,172. It still
falls short of being fast enough to keep up with the modern world of testing needs, not to
mention the need to move away from using horseshoe crab blood in order to protect their
dwindling population. bWBA and MAT are similar to LAL in that they fall short on
keeping up with the needs of the modern world. While they present attractive qualities,
MAT being able to use recycled monocytes from blood banks and bWBA requiring very
little preparation, they still require collection and storage of blood from living beings.
This would create difficulties in collecting proper amounts of blood stores to handle
testing requirements. These traditional endotoxin detection assays also suffer from
masking of endotoxins by the constituents present in drug formulations when spiked with
endotoxins (LER phenomena) 62-64. This poses potential risks of underestimated
endotoxin contamination in pharmaceutical products. Electrochemical techniques offer
nearly endless combinations of sensor and protein-complexes, able to be designed
specifically for a testing solution that could prove difficult for other tests. Optical
detection methods offer incredibly high precision testing, with results ready in a matter of
seconds, provided the equipment can be afforded and operated correctly. Finally, with the
rise of mass-based resonance detection, the future of detection methods relies on more
accurate, real-time detection, with increasingly cheap and easy to use. A reliable
analytical method for endotoxin detection and analysis will also serve as a useful tool in
the monitoring of drinking water purification processes and water reclamation plants.
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There is no single purification method that fits all separation scenarios 173. The
method chosen will depend greatly on the properties of the target molecule 139.
Ultrafiltration is well suited for removing endotoxins from water, salts, or small molecule
therapeutics, but it is not applicable to most separation scenarios. Extraction provides a
high endotoxin removal efficiency for highly contaminated samples, but can possibly
lead to an undesirable level of product loss. Ion Exchange chromatography provides
adequate separation with acceptable product loss for molecules with a weak positive
charge. Anion exchange chromatography is the most commonly used method for
endotoxin removal. Endotoxin has been removed from plasmid DNA influenza vaccine
solutions using ion-exchange chromatography with 97% purity and 47-88% yield 174,175.
Due to the specificity of the ligands, affinity chromatography and mixed-mode
chromatography offer an adequate separation with high product recovery for a wide range
of therapeutic monoclonal antibodies. Membrane adsorption offers a reduced processing
time and initial cost with a high product recovery, but has a low binding capacity that
limits removal efficiencies. While there is no single method that is applicable to all
scenarios, ion-exchange, affinity, and mixed-mode chromatography all offer consistently
high removal efficiencies and product recoveries under appropriate operating conditions.
Even so, additional research is needed to develop more widely applicable and costeffective methods that reduce product loss while meeting all governing regulations for
endotoxin concentrations in biopharmaceutical products.
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1.6. CONCLUSION
There is an increased demand for techniques capable of producing quality
products at a decreased cost. This is especially true for biopharmaceuticals produced
using gram-negative bacteria, where endotoxin contamination is a concern. Animal-based
endotoxin detection techniques will become obsolete in favor of electronic biosensors or
fluorescence-based techniques. Developing endotoxin removal methods that are both
effective and cost efficient is an ongoing challenge due to the high purity required and the
potential interactions present between endotoxins and target molecules. Affinity and
mixed-mode chromatography are the most promising methods for a widely applicable
removal methods due to the highly selective interactions between endotoxins and the
chosen ligand. Additional research is still required to further develop additional methods
for removal and ligands that demonstrate a high affinity to endotoxins with a low toxicity
and cost. These innovations will allow for an increase in product quality and yield with a
decrease in manufacturing cost.

1.7. DISSERTATION OVERVIEW
In paper-1, biocompatible and recyclable polymeric polycaprolactone (PCL)
nanoparticles (NPs) (𝑑 = 780 ± 285 𝑛𝑚) were synthesized at a relatively low cost and
demonstrated to possess sufficient binding sites for endotoxin adsorption and removal
The PCL NPs removed ~82% and ~90% endotoxins from water and protein solution
using only one milligram (mg) of NPs, which was equivalent to ~1.23 × 10 and
~1.45 × 10 endotoxin units (EU) per mg of particle. The endotoxin removal efficacy
increased to a higher level (~98% and ~99%) when phosphate buffered saline (PBS; 150
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mM NaCl) was used in place of water and in proteins. In addition to high endotoxin
removal efficiency the protein recovery values were > 95 % for a wide concentration
range of protein solutions (20 – 1000 g/ml). The PCL NPs were also highly effective in
different buffers and pHs. To scale up the process even further and increase the
throughput, PCL NPs were incorporated into a matrix of cellulose acetate membrane
which enhanced the endotoxin adsorption further up to ~100% just by running the
endotoxin-containing water through the membrane under gravity.
In paper-2, The goal was to test the validity of the hypothesis that synergistic
combination of van der Waals and hydrophobic interactions were responsible for
endotoxin binding on polycaprolactone (PCL) nanoparticle’s (NPs) surface. This
hypothesis was tested by evaluating endotoxin removal efficiency of a material which
shows surface hydrophobicity similar to that of PCL NPs. Polystyrene (PS)
nanoparticles,~ 800 𝑛𝑚, with surface properties similar to PCL NPs were used as a
control to test the hypothesis. Additionally, this work demonstrated that acidic (pH 2.8)
and basic (pH 11.5) conditions do not have a major impact on protein recovery using
PCL NPs. Six different types of proteins with molecular weights varying from 14 kDa
- 341 kDa and isoelectric points (pI) from 4.5-10.7 showed protein recovery > 92 %
under extreme operating pH. Finally, in order to increase the throughput and address the
mass transfer limitations, the PCL NPs incorporated cellulose acetate (CA) biofilter were
synthesized and applied to different protein solutions with a maximum endotoxin
removal efficiency ~ 99 % and protein recovery >92 %.
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ABSTRACT

The presence of endotoxin, also known as lipopolysaccharides (LPS), as a side
product appears to be a major drawback for the production of certain biomolecules that
are essential for research, pharmaceutical, and industrial applications. In the
biotechnology industry, gram-negative bacteria (e.g., Escherichia coli) are widely used to
produce recombinant products such as proteins, plasmid DNAs and vaccines. These
products are contaminated with LPS, which may cause side effects when administered to
animals or humans. Purification of LPS often suffers from product loss. For this reason,
special attention must be paid when purifying proteins aiming a product as free as
possible of LPS with high product recovery. Although there are a number of methods for
removing LPS, the question about how LPS removal can be carried out in an efficient and
economical way is still one of the most intriguing issues and has no satisfactory solution
yet. In this work, polymeric poly-ε-caprolactone (PCL) nanoparticles (NPs) (𝑑 = 780 ±
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285 𝑛𝑚) were synthesized at a relatively low cost and demonstrated to possess sufficient
binding sites for LPS adsorption and removal with ~100% protein recovery. The PCL
NPs removed greater than 90% LPS from protein solutions suspended in water using only
one milligram (mg) of NPs, which was equivalent to ~1.5 × 10 endotoxin units (EU)
per mg of particle. The LPS removal efficacy increased to a higher level (~100%) when
phosphate buffered saline (PBS containing 137 mM NaCl) was used as a protein
suspending medium in place of water, reflecting positive effects of increasing ionic
strength on LPS binding interactions and adsorption. The results further showed that the
PCL NPs not only achieved 100% LPS removal but also ~100% protein recovery for a
wide concentration range from 20 – 1000 μg/ml of protein solutions. The NPs were
highly effective in different buffers and pHs. To scale up the process further, PCL NPs
were incorporated into a supporting cellulose membrane which promoted LPS adsorption
further up to ~100% just by running the LPS-containing water through the membrane
under gravity. Its adsorption capacity was ~2.8 × 10 EU/mg of PCL NPs,
approximately 2 -fold higher than that of NPs alone. This is the first demonstration of
endotoxin separation with high protein recovery using polymer NPs and the NP-based
portable filters, which provide strong adsorptive interactions for LPS removal from
protein solutions. Additional features of these NPs and membranes are biocompatible
(environment friendly) recyclable after repeated elution and adsorption with no
significant changes in LPS removal efficiencies. The results indicate that PCL NPs are an
effective LPS adsorbent in powder and membrane forms, which have great potential to be
employed in large-scale applications.
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1. INTRODUCTION

In biotechnology industries, gram-negative bacteria are widely used for the
production of therapeutic biomolecules including proteins, peptides, and nucleic acids 1–6 .
These biomolecules are recovered by cellular rupturing that leads to the release of a large
number of bacterial cell-wall components containing endotoxins, also known as
lipopolysaccharides (LPS)7–9 . When the LPS contaminated products are administered to
animals or humans even in small quantities (0.05–0.1ng/ml), a systemic inflammatory
reaction can occur, leading to multiple pathophysiological effects, such as septic shock,
tissue injury, and lethality10,11. Removing undesirable LPS from solutions is thus an
important aim in the pharmaceutical industry and in clinical practice. Conventional
treatments such as coagulation and membrane filtration are adequate for removing
bacteria cells and debris but not effective for removing dissolved endotoxins to a
significant extent. Therefore, it is highly desirable and also the focus of this project to
develop a biodegradable and inexpensive means that can tackle both aspects of LPS
removal.
A number of approaches have been developed and typically utilized to reduce
LPS concentration in pharmaceutical solutions and therapeutic products or in purified
water8,12–33. These approaches employ activated carbon 34,35, gel filtration
chromatography12–15, ion exchange or size exclusion chromatography16–20, sucrose
gradient centrifugation36–38, Triton X-114 phase separation39–41, ultrafltration21,22,
microfltration21,22 and affinity adsorbents23–28, functionalized with L-histidine42,
poly(ethylene imine) (pEI)23, poly-ε-lysine, poly(γ-methyl L-glutamate), or polymyxin
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B8,29–33 and chemical means such as ozonation and chlorination 35,43. More recently,
nanoparticle (NP)-based methods have also been attempted and shown great promise 44–46.
Polymyxin B capped silver (Ag) NPs have been used to remove LPS from aqueous
solutions, up to 97% efficiency, based on the ionic interaction between the cationic
peptide on Polymyxin B and the anionic phosphate on Lipid A of LPS 44. Surface
modified iron oxide (Fe3O4) gold (Au) core-shell nanoflowers (NFs) have been explored
for simultaneous reduction and detection of LPS as alternatives to classical methods of
endotoxin sensing47. Also, NPs with a polystyrene core and a polyglycidyl methacrylate
shell have been synthesized and further modified with amine-based, amino acid based,
PEI, tetracaine, or Polymyxin B ligands for LPS removal from water and salt solution 46.
The parent particles modified with amine-based (ethylene diamine, hexamethylene
amine, and dodecyl diamine) and PEI ligands showed significant LPS removal efficiency
around 90% from both water and salt solution, whereas those modified with tetracaine,
amino acid lysine, and amines (histamine and tryptamine) showed a higher LPS removal
efficiency from water, also around 90%, than from salt solution46. While showing great
promise, these approaches at present still have their shares of limitations and
disadvantages in terms of cost, efficiency, degradability, side effects, and/or
accompanying toxicity brought by the reagents. For examples, the methods utilizing
porous functionalized NPs are reasonably effective in reducing the LPS concentration;
however, their operations are relatively expensive due to the use of high-pressure
equipment that adds significant cost to downstream purification and are contingent on the
slow processes of intraparticle diffusion and solute retention on the binding sites 48–50.
Polymyxin B, a polypeptide antibiotic, can also cause neurotoxicity and nephrotoxicity.
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A key step forward with the NP-based approach is to establish a high throughput, lowcost method that is not subject to high pressure-drop limitation, slow solute transport, or
accompanying toxicity. To this end, poly-ε-caprolactone (PCL) NPs without any
modification have been manufactured in the PI’s laboratory, which are non-porous solid
adsorbent nanoparticles with solute binding sites situated on the particle surface. The NPs
were found to be capable of adsorbing and removing LPS from protein solutions at
efficiency up to 100%. Their prospects for technological application were further
substantiated by the processing feasibility of incorporating PCL NPs into membrane
filters and high LPS reduction and removal from biological solutions using cellulose
membranes embedded with PCL NPs. In either powder form or in a spread bed of a fat
sheet membrane, PCL NPs offer high adsorption capacity per unit mass of the adsorbents.
Since PCL and cellulose are both low-cost biocompatible polymers 51–53, the use of such
PCL NP-embedded membranes represents a novel LPS separation system that requires
low capital costs but provides desirable ease of manufacturing, excellent performance,
disposability, and biodegradability.

2. MATERIALS AND METHODS

2.1. SYNTHESIS OF PCL NANOPARTICLES
PCL NPs were synthesized by the solvent evaporation method which utilized
high–speed homogenization and sonication, followed by solvent evaporation,
centrifugation to remove surfactants, and then lyophilization.54-58 A PCL solution at a
concentration of 10 mg/ml in ethyl acetate was injected using a syringe pump to a 1%
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w/v polyvinyl alcohol (PVA) solution prepared with reverse osmosis (RO) water. The
mixture was homogenized by using a homogenizer rotating at 3000 rpm while being
placed in a sonication bath. Ethyl acetate was removed by stirring the mixture at 300 rpm
for two days. The obtained particles were washed five times using RO water and
centrifuged for 30 minutes at 10,000 rcf. The resulting products were freeze-dried,
weighed, and stored at 4ºC until further use. To test the effects of cationic charges on
bare PCL NP, 10 mg of freeze-dried PCL NPs were coated with cationic PLL solution by
incubating with 1 ml of 0.1 % (w/v) PLL (Sigma) for 1 h. Post incubation the particle
suspension was centrifuged for 30 min at 16,000 rcf and the supernatant was separated to
obtain positively charged PLL coated PCL NPs.

2.2. CHARACTERIZATION OF PCL NANOPARTICLES
The morphology of PCL NPs was observed using Hitachi S-4700 scanning
electron microscope (SEM) at an accelerating voltage of 15 kV. Samples were sputter
coated with Denton Au/Pd coater before inserting it into the microscope. The average
PCL particle size was measured by analyzing the SEM images using the ImageJ software
(version 1.51w). The average particle size was reported as mean ± standard deviation
(SD) based on the diameters of 200 randomly selected particles. The hydrodynamic size
and surface charge of NPs were characterized by dynamic light scattering (DLS) and zeta
(𝜁) potential measurements, respectively using Malvern NanoZS90 Zetasizer. The
hydrodynamic diameter of PCL NPs was measured at 25ºC using He-Ne Lasers at 90º
scattering angle. The size distribution was obtained based on three independent
experiments utilizing 100 successive runs. Zeta potential values were reported based on
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three independent experiments with each experiment utilizing 15 successive runs and the
results were reported as millivolts (mV) ± SD.

2.3. ADSORPTION STUDIES
Escherichia coli O111 : B4 LPS (Sigma Aldrich) was used to study the adsorption
capacities of PCL NPs in aqueous solutions in batch experiments. Initial experiments
were carried out using a constant LPS concentration (150 µg/ml) treated with different
PCL concentrations (0.1, 25, 50, 100, 200, 300, 400, 500, 750 and 1000 μg/ml) in: (i) RO
water (pH ~6); (ii) phosphate buffered saline (PBS; 150 mM, pH ~7.4); (iii) bovine
serum albumin (BSA) solutions in water and PBS; (iv) Trastuzumab (TTZ; Genentech)
solutions in water and PBS; (v) Fibrinogen (Alfa Aesar) in PBS and (vi) Human
Hemoglobin (MP Biomedicals) in PBS. The composition of PBS is as follows: 137 mM
NaCl, 10 mM phosphate, and 2.7 mM KCl at 25°C. The LPS binding capacity to PCL
NPs was analyzed using Bodipy (BOD) fluorescence displacement assay technique. 58,59
BOD is a fluorescent molecule that quenches its fluorescence intensity (F.I.) when it
binds to LPS. The F.I. of BOD was used to determine the LPS concentration in solution
using a known standard calibration curve (Figure. S1 and Figure. S2). The F.I.
measurements were carried out using a microplate reader (BioTek). Excitation and
emission wavelengths for BOD were 485/20 and 528/20 nm, respectively. RO water was
used as a negative control. The background fluorescence intensities were subtracted to
avoid any interferences. The percentage (%) LPS removal by PCL NPs from water and
PBS was calculated using equation (1):
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The % LPS removal by PCL NPs from protein solutions was calculated using
equation (2):
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The adsorption capacity at equilibrium (𝑞 ) was evaluated using the following
equation:
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where 𝐶 , 𝐶 , 𝑊, and 𝑉 represent the initial LPS concentration (g/ml), the
corresponding LPS concentration at equilibrium (g/ml), the PCL NP’s mass amount
(mg), and the solution volume (ml), respectively. The isotherm data were fitted into
the linear Freundlich model equation (4) to describe the adsorption equilibria:
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where, 𝑞 , 𝐾, 𝑛 and 𝐶 represent the adsorption based binding capacity (g LPS per
mg PCL NPs), Freundlich (binding affinity) constant (μg LPS per mg PCL NPs),
Freundlich exponent and equilibrium LPS concentration (μg LPS/ml solution),
respectively.

2.4. PROTEIN RECOVERY
Protein recovery in LPS spiked sample solutions was quantified using BCA assay
kit (Pierce). The absorbance at 562 nm was measured in a microplate reader (BioTek).
Different concentration of BSA, TTZ, fibrinogen and human hemoglobin were used for
plotting the individual protein’s standard curves (Figure. S3). All assays were performed
by the manufacturer’s instructions.

2.5. EFFECTS OF BUFFER AND pH ON LPS REMOVAL
The effect of different buffers on LPS binding efficiency was analyzed by
interacting a fixed PCL NP concentration (1000 µg/ml) with a constant LPS
concentration (150 µg/ml) prepared using different buffer solutions recipes (Table S1)
each having fixed ionic strength of 100 mM (0.1 M). Six different buffer pH values from
2.8-9.6 were tested. Glacial acetic acid was used to obtain a pH value of 2.8. Phosphate
buffers were prepared from monobasic and dibasic salts of 0.2 M sodium phosphate to
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obtain pH values of 5.8, 6.8 and 8.60-62 PBS of sodium bicarbonate were used to prepare
pH 7.4 and 9.6 buffers, respectively.60-62

2.6. EFFECT OF SALT CONCENTRATION ON PROTEIN RECOVERY
To investigate the effect of salt concentration on % protein recovery, 1000 μg/ml
of each BSA and TTZ were spiked with 150 μg/ml of LPS in the different range of PBS
concentrations: 0, 0.1, 1, 10, 100 and 150 mM. Protein concentrations were measured
before and after LPS spiking and used to further calculate the % protein recovery.

2.7. PCL NP REGENERATION STUDIES
PCL NP suspension was interacted with fixed LPS concentration (270 µg/ml) in
RO water and then centrifuged to obtain the supernatant which was reacted with BOD to
calculate the percent LPS removal efficiency using equation (1). The PCL NP pellet was
resuspended in 0.2 N sodium hydroxide (NaOH) solution for 2 h and then centrifuged to
remove the NaOH supernatant. The PCL NP pellet was washed five times using RO
water before reusing it again for LPS binding. This regeneration cycle was repeated three
times to measure any loss in LPS binding efficiency for PCL. The LPS removal
efficiency of PCL NPs after each washing cycle was measured using the BOD
fluorescence assay.

2.8. SYNTHESIS OF CELLULOSE ACETATE (CA) MEMBRANE
The CA membranes with or without PCL NPs were prepared by a non-solvent
induced phase separation process.63 A casting solution was prepared by dissolving 10
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wt.% each of CA and 5 wt.% Pluronic F127 in dimethyl sulfoxide (DMSO) (control). For
membranes with NPs, 1 wt.% of PCL NPs was dispersed in the casting solution under
vigorous stirring (1100 rpm) at 50ºC for 1 h to allow homogenous mixing and the
solution was then left for 2 h to allow the complete release of bubbles. The final solution
was cast on a casting plate and then immersed in RO water coagulation bath for 30 min.
Finally, the water wet membrane was immersed in 30% glycerol (plasticizer) for 15 min,
which in addition to improving the mechanical properties also help in dry storage of the
membrane for at least 300 days with no major loss in membrane flux and removal
properties.64 The mass loading of PCL NPs in CA membranes was quantified by
comparing the weights of 10 randomly freeze-dried membrane pieces of the same area
(1.8 cm2) before and after adding the NPs. The measured weight difference of the
membranes with and without NPs is the mass of PCL NPs added to the membrane and
was used to calculate LPS removal per unit mass of PCL NPs.

2.9. MICROSCOPY AND MICROANALYSIS
The CA membranes with or without PCL particles were dried using the freezefracture method.65 Samples were attached to an SEM stub and sputter coated with Denton
Au/Pd coater. The membrane surface and cross sections were imaged using the Hitachi S4700 SEM operated at 3 kV. The membrane surface and cross-sectional morphology,
pore size, and thickness were analyzed using ImageJ software (version 1.51w). The
average membrane pore size and thickness were based on 100 randomly selected pores
and points from different images. The results were reported as average ± standard
deviation (SD). The presence of PCL NPs in the membrane was further verified using
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fluorescein isothiocyanate (FITC; 1wt%) incorporated PCL NPs and fluorescence
microscopy (Zeiss) equipped with 470 ± 40/525 ± 50 nm excitation/emission filters.

2.10. PERMEATION STUDIES
The measurement of permeation flux was conducted using a custom-made
membrane test apparatus (Figure. S4). The apparatus was made of two polyvinyl chloride
flow pipes that hold the membrane in between like a sandwich. Each flow pipe is 1.5 cm
wide. The top and bottom pipes are 20 cm and 10 cm long, respectively. The membrane
area was 1.8 cm2. In each experiment, a volume of 20 ml water or solution was fed to the
top pipe in a batch setup and flowed through the membrane by gravity. For LPS mixed
water, a concentration of 270 μg/ml LPS in 20 ml water was used. Water was collected
from the end of the bottom pipe. The water volume was measured at 1 h interval for 8 h
to calculate the change in water flux.

2.11. QUANTIFICATION OF LPS REMOVAL USING PCL NPs IN CA
MEMBRANES
The determination of LPS removal by CA membranes with or without PCL
particles was also carried out by BOD fluorescence displacement assay technique 58,59 and
the apparatus introduced above. A volume of 20 ml RO water containing 270 μg/ml of
LPS was fed to the top flow pipe to flow through a sandwiched membrane by gravity. A
fixed volume (277 µL) of the LPS feed and the permeate was collected every hour until 8
h. The samples were mixed with BOD (262.11 µg/ml) and the F.I. of BOD was measured
using a plate reader (BioTek). The percent (%) LPS removal was calculated using
equation (5),
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Cumulative % LPS removal  (1 
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FI BOD  FI BOD. LPS in permeate
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)

5

are the F.I.s of BOD alone,

BOD mixed with LPS in permeate, and BOD mixed with LPS in the feed solution,
respectively. Each value used here was based on triplicate measurements from three
independent experiments. The mean differences and standard deviations were also
evaluated.

2.12. CALCULATION OF LPS REMOVAL EFFICIENCY PER UNIT MASS AND
SURFACE AREA OF PCL NPs
The LPS removal efficiency per unit mass and surface area were calculated for
PCL NPs used in powder form or in the CA membrane. This required the calculation of
the number of PCL NPs per unit solution volume using equation (6).

Number of PCL

NPs 6c  1012

ml
 d p 3

 6

where 𝑐 is the concentration of particles in solution in g/ml, 𝜌 is the density of PCL NPs
in g/ml, and 𝑑 is the particle diameter in µm. The mass loading of PCL NPs entrapped
in a CA membrane was measured from the mass difference of the freeze-dried CA
membranes with and without NPs. The LPS removal efficiency per unit cm 2 and per unit
milligram of NPs was calculated based on the mass of LPS in the feed solution and the
maximum % LPS removal.
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3. RESULTS

3.1. REMOVAL OF LPS FROM WATER AND PBS USING PCL NPs IN
POWDER FORM
The size of PCL NPs was observed to be 780 ± 285 nm in diameter by analyzing
SEM images (Figure. 1a) and DLS technique (Figure. 1b), which, relatively speaking, is
fairly uniform with a low level of dispersity in size. The surface morphology shows that
the NPs were of highly spherical shape and their surfaces appeared to be closely packed
without apparent pores leading into the interior of the particles. The 𝜁 potential of PCL
NPs was found to be −20 ± 5 mV in water (Figure. 1c) indicating a stable dispersion that
resists aggregation. LPS adsorption tests were carried out with PCL NPs in both water
(open circles; dotted line; Figure. 2a) and PBS (filled, solid 265 circles; solid line; Figure.
2a) where initially the concentration of PCL NPs was systematically varied from 0 to
1000 μg/ml in both cases at a fixed LPS spiked concentration of 150 μg/ml and then the
concentration of PCL NPs was fixed and the concentration of LPS was varied from 0.1 to
150 μg/ml in RO water. It was clear and important to note first that PCL NPs were
effective in adsorbing and removing LPS from solutions regardless of the presence or
absence of salts (PBS). In general, the removal efficiency of LPS by PCL NPs increased
with increasing PCL NP concentration, which was to be expected due to increasing
numbers of active sites available in the system for binding to LPS. The maximum level of
LPS removal achieved was 98% when the PCL NP concentration of 𝑐=1000 μg/ml was
used under the positive influence of salts. Without salts, the LPS sequestration from
water was only ~1.8% at a low NP concentration of 0.1 μg/ml and increased to 9% and
82% when the NP concentration became 100 and 1000 μg/ml, respectively. The result
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at 𝑐 =1000 μg/ml was used to evaluate the LPS removal efficiency with varying LPS
concentrations of 0–150 μg/ml in water (Figure. 2b). The maximum LPS removal
efficiency was ~95%, which was approximately ~ 2040 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑢𝑛𝑖𝑡𝑠 (𝐸𝑈)/𝑐𝑚 or
~1.3 × 10 𝐸𝑈/𝑚𝑔 of PCL NPs (Table S2).Across the whole concentration range, the
LPS adsorption increased with the addition of salt (PBS; pH 7.4) to water (solid circles;
Figure. 2a). This positive effect was clearly exhibited by the data beyond any uncertainty
of measurement and indicated that increased ionic strength by the addition of salts
resulted in higher LPS adsorption on the PCL NP surface. It is possible that at this high
salt concentration (150 mM PBS) a strong interaction between water molecules and salts
creates a shielding off effect leaving less water available for the induction of interactions
between LPS and PCL. This behavior is consistent with the previously published
literature.66-71 Another possible explanation could be an electrostatic screening effect that
reduces the repulsive interaction between two moieties carrying the same type of charges.
Although both LPS and PCL can generally be considered hydrophobic molecules, the
former exhibits a net negative charge due to its phosphate groups 33 and the latter also
possesses partial negative charges in its carbonyl oxygen atoms. The repulsion between
these negative charges can be understood to be weak relative to the van der Waals and
hydrophobic binding46 between the two massive molecules and hence unable to impede
the overall binding interaction and adsorption between LPS and PCL. However, this
repulsion can be further weakened, thereby giving rise to stronger binding interaction and
heightened adsorption, by the presence of salt ions in proximity to the negative charges
that shield their like-charge interactions.
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Figure 1. Characterization of PCL NPs. (a) An SEM image of PCL NPs at 50,000 X
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL
NPs in water. Three colors indicate three independent runs.
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(c)

Figure 1. Characterization of PCL NPs. (a) An SEM image of PCL NPs at 50,000 X
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL
NPs in water. Three colors indicate three independent runs (cont.).

(a)

Figure 2. The LPS removal efficiency of PCL NPs from water and PBS. (a) The percent
(%) LPS removal from water (open circles, ○; dotted line) and PBS (filled, solid circles,
● ; solid line) following adsorption on PCL NPs. *** indicates the p-value < 0.005
showing a statistically significant difference between % LPS removal in water and PBS.
A fixed LPS concentration of 150 μg/ml was used in this study. (b) Water containing low
(0.1 μg/ml) to high (150 μg/ml) LPS concentrations were treated with 1000 μg/ml of PCL
NPs that gives ~95% LPS removal.
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(b)

Figure 2. The LPS removal efficiency of PCL NPs from water and PBS. (a) The percent
(%) LPS removal from water (open circles, ○; dotted line) and PBS (filled, solid circles,
● ; solid line) following adsorption on PCL NPs. *** indicates the p-value < 0.005
showing a statistically significant difference between % LPS removal in water and PBS.
A fixed LPS concentration of 150 μg/ml was used in this study. (b) Water containing low
(0.1 μg/ml) to high (150 μg/ml) LPS concentrations were treated with 1000 μg/ml of PCL
NPs that gives ~95% LPS removal (cont.).
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3.2. REMOVAL OF LPS FROM PROTEIN SOLUTIONS USING PCL NPs
To study the effectiveness of PCL NPs on removing LPS at the common
contamination level from 0–150 μg/ml in biopharmaceutical solutions, two protein
solutions were investigated. For this purpose, BSA and TTZ protein solutions (~1 mg/ml)
in PBS of pH 7.4 and RO water containing either low or high levels of LPS were exposed
to 1000 μg/ml PCL NPs (Figure. 3a). It is worth noting that the % LPS removal was
higher (90–100%) in PBS (solid lines, Figure. 3a) than in water (dotted lines, Figure. 3a)
indicating that PCL NPs were effective in removing LPS from pharmaceutical protein
formulations.72 We further tested the effects of protein concentration on LPS removal by
analyzing four different protein solutions spiked with a fixed concentration (150 μg/ml)
of LPS (Figure. 3b). Increasing protein concentrations from 250 to 1000 μg/ml did not
alter the ~90% LPS removal efficacy in PBS (solid lines, Figure. 3b) by PCL NPs (1000
μg/ml). In the case of BSA and TTZ in water, the % LPS removal dropped from 95% to ~
80% with the increment in protein concentrations. This reduction of LPS binding on PCL
NPs at high protein concentrations in water could be either due to: (i) exchange of low
affinity of the highly abundant protein binding with the NP surface by the lower
abundance of LPS with a higher affinity for the NP surface; and/or (ii) formation of large
aggregates between LPS-protein molecules desorbing LPS from the NP surface. In PBS,
the % LPS removal from protein solutions was higher than that in water presumably due
to more stable LPS-PCL NP complex formation surrounded by ions in bulk solution. On
a preparative scale, an important indicator of desirable properties from such NP
adsorbents is the adsorption capacity per unit mass. For this purpose, the equilibrium LPS
adsorption capacity of PCL NPs was calculated up to 1.4 × 10 𝐸𝑈/𝑚𝑔 with ~100%
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LPS removal capacity from BSA, TTZ, fibrinogen and human hemoglobin solutions in
PBS of pH 7.4 (Table S3-S6).

(a)

(b)

Figure 3. The LPS removal efficiency of PCL NPs from protein solutions. (a) Increasing
LPS or (b) protein concentrations have no significant effect on the % of LPS removal
from protein solutions prepared in water and PBS. Symbols ● , ○, ∎, ▲ ,♦ indicate LPS
containing BSA solutions in PBS, BSA in water, trastuzumab (TTZ) solutions in PBS,
TTZ in water, Fibrinogen in PBS and Human hemoglobin in PBS respectively.
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3.3. LPS ADSORPTION BEHAVIOR ON PCL NPs
Based on the experimental data of LPS binding on PCL NPs, binding-dependent
parameters were calculated using the Freundlich isotherm model that rationalizes the
contribution of favorable adsorption on the NP surface. The experimental data fit the
Freundlich model (R2 >0.98) where the slope

accounts for the intensity of adsorption

and intercept, 𝐾 measures the binding affinity (μg LPS/mg PCL NPs) (Figure. 4). 𝑛 > 1
represents favorable adsorption associated with multilayer LPS formation on the PCL
surface.73,74 From Table S7, it can be seen that the binding intensity (n) values vary from
1.1 – 1.4 thus indicating that the NPs have favorable LPS binding adsorption
performance for all tested conditions.75 The binding affinity constant, 𝐾 was found to
vary between 9.5 – 11.7 μg LPS/mg PCL NPs (~ 105-106 EU/mg) depending on the
solution (water and PBS) and protein types (BSA and TTZ). The 𝐾 values were
compared with previously reported sorbents76-79 which indicated that PCL NPs were 10 to
40 log orders of magnitude better in LPS binding capacity than most of the commonly
used adsorbents such as Polymyxin B conjugated cellulose microspheres and Histidine
immobilized silica gels, among others.76-79 To ease out the interactions between LPS and
PCL NPs, the NPs were coated with a cationic polymer, PLL (Figure S5). The PLL
coated PCL NPs showed a significant decrease in % LPS removal from 80% to 60% in
water and from 100% to 20% in PBS. These findings reassert the selective hydrophobic
interactions between LPS and PCL NPs.
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Figure 4. Freundlich adsorption isotherm fitting of LPS removal by PCL NPs from BSA
and TTZ solutions in water and PBS.

3.4. PROTEIN RECOVERY
Most biopharmaceutical purification processes suffer from product loss. Protein
recovery is as important as LPS removal to reflect an interaction of the protein with LPS
binding sites. Figure. 5 shows the results of protein recovery at varying (a) LPS and (b)
protein concentrations. As it is seen that protein recoveries were close to 100% for a wide
range of LPS (0 – 160 μg/ml) and protein (0 – 1000 μg/ml) concentrations. These results
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further confirm the selectivity of PCL NPs for LPS while showing 100% protein
recovery.

(a)

Figure 5. Percentage of protein recovery as a function of (a) protein concentrations and
(b) LPS concentrations. The amount of PCL NPs used was 1000 μg/ml.
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(b)

Figure 5. Percentage of protein recovery as a function of (a) protein concentrations and
(b) LPS concentrations. The amount of PCL NPs used was 1000 μg/ml (cont.).

3.5. EFFECT OF pH ON LPS REMOVAL IN DIFFERENT BUFFER
CONDITIONS
The percentage of LPS removal was predicted to be dependent on the changes in
buffer pH (Figure. 6a). LPS binding on PCL NPs show reasonably strong dependence on
pH for different buffers of variable pHs. The ionic strength for all buffers was maintained
constant at 100 mM (0.1 M). At the pH of 2.8, i.e., near and below the isoelectric point
(pI 2) of LPS,80 the binding of LPS with PCL NPs increased close to ~90% possibly due
to low LPS solubility near the pI and high hydrophobic interactions between non-polar
LPS and PCL resulting in increased LPS removal from the solution. On the other hand
above the pI of LPS, at pHs between 5.8 and 8, average LPS removal efficiencies were
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found to be increased from 30% up to 90% in an alkaline buffer pH of 9.6. The
enhancement in LPS removal at high pH is most likely due to hydrophobic interactions
between non-polar LPS and PCL NPs that segregate the polar ions and water molecules
and minimizes the area of contact between polar and nonpolar molecules in the
solution.81 The phase separation of LPS was further enhanced up to ~99% by PBS of
higher ionic strength (0.15 M, pH 7.4) driving the self-assembly of LPS-PCL NP
hydrophobic effects. In summary, PCL NPs can operate in acidic to neutral conditions
(pH 2.8 to pH 9.6). The highest LPS removal (~100%) was found in PBS of pH 7.4
followed by >85% recovery in acetic acid and sodium bicarbonate buffer of pH 2.8 and
9.6, respectively.

(a)

Figure 6. The effects of pH and salt concentrations on LPS removal by PCL NPs. (a) The
effect of pH and buffers on the % LPS removal. Four different types of buffers (acetic
acid, phosphate, PBS and sodium bicarbonate) covering pH range from 2.8-9.6 were
used. (b) Dependence of protein recovery on salt concentrations in LPS and PCL NP
systems. Solid line with filled, solid circles (●) represents BSA and the dotted line with
filled, solid squares (∎) indicates TTZ.
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Figure 6. The effects of pH and salt concentrations on LPS removal by PCL NPs. (a) The
effect of pH and buffers on the % LPS removal. Four different types of buffers (acetic
acid, phosphate, PBS and sodium bicarbonate) covering pH range from 2.8-9.6 were
used. (b) Dependence of protein recovery on salt concentrations in LPS and PCL NP
systems. Solid line with filled, solid circles (●) represents BSA and the dotted line with
filled, solid squares (∎) indicates TTZ (cont.).

3.6. EFFECT OF SALT CONCENTRATION ON PROTEIN RECOVERY
Figure. 6b shows that the % protein recovery is almost linear that varies between
90 to 100% with the change in salt concentrations indicating that the ionic strength has a
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little effect on protein recovery in our LPS-PCL NP system. At low salt concentrations
extrapolated from zero salt concentration (water), the recovery was >90% for both BSA
and TTZ which were increased further up to ~100% at higher salt concentrations (150
mM). These results indicate that the low affinity of proteins towards PCL NPs both in the
absence and presence of solution ions. The mutual interactions between LPS and PCL
NPs keep protein away in the bulk phase. At higher ionic strength, it is possible that free
ions rearrange themselves into certain configuration around LPS-PCL NP complexes and
proteins that promote increased retention of proteins in the mixture and thus slightly
decrease the protein recovery to ~95%.

3.7. PCL NPs WERE REGENERATED TO REMOVE LPS
PCL NPs were regenerated by breaking LPS-PCL complexes in RO water which
makes the LPS removal process more efficient and scalable (Figure. 7). NaOH was used
to regenerate the PCL NPs that exchanged off LPS for the hydroxide (𝑂𝐻

) ion in the

caustic solution which is well-known to desorb LPS from chromatography resins and
particles quite effectively.82-84 The collected PCL NPs were re-dissolved off the (𝑂𝐻

) ,

and this is facilitated by the 2 h contact time. A high LPS (EU/ml) recovery (~80%) was
observed over the course of three regeneration cycles. An average LPS recovery of > 2 ×
10 EU/ml was obtained per regeneration cycle when LPS bound PCL particles were
reacted with 0.2 N NaOH for 2 h and then washed using RO water before being reused
for LPS binding again. Overall, the LPS removal efficiency of PCL NPs nearly had any
change after three rounds if adsorption, elution, and reuse.
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Figure 7. PCL NP regeneration. LPS removal efficiency after PCL NPs is regenerated
three times by desorbing LPS from the NPs using 0.2 N NaOH and testing for LPS
adsorption/removal.

3.8. PCL NPs WERE EMBEDDED IN CA MEMBRANES
The cross-sections of CA membranes were obtained by SEM (Figure. 8a) and
compared with and without NPs. The original CA membrane exhibited a thickness of 116
± 2 μm and a relatively homogeneous macrostructure with a distinctive dense layer near
the surface (Figure. 8a). Simply from the point of view of the ratio (~100) between the
membrane thickness and the particle diameter, the presence of PCL NPs could be
expected to have a great impact on the structural and transport properties of the
membrane. Indeed, the CA membrane with PCL NPs showed a seemingly more uniform
cross-sectional structure with no unique layer (Figure. 8b), which was revealed
fluorescence microscopy to contain green dye-labeled spherical PCL particles on the flat
surface of the membrane (Figure. 8c). The cavities in the PCL embedded membrane were
found to be noticeably larger than those in the original CA membrane as visualized from
the SEM images of their cross-sections (Figures. 8a and 8b). While the incorporation of
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PCL NPs in the membrane appeared not to affect the pore opening size as there was only
a slight change from 0.16 ± 0.05 μm to 0.17 ± 0.05 μm (Figure. S6), it has much greater
impact on the membrane’s macro-void cross-sectional morphology as it changed from a
narrow, tortuous, and flaky pore structure (Figure. 8a) to a broad, straight, and finger-like
pore structure (Figure. 8b).63,85-90 PCL NPs also increased the membrane thickness by
more than 13%, from 116 ± 403 2 μm to 132 ± 12 μm (Table S8).

(a)

Figure 8. Characterization of PCL NP embedded filter. SEM images of the cross-sections
of membranes prepared from (a) CA membrane, scale bar = 100 μm, (b) CA membrane
with PCL NPs in low magnification, scale bar = 100 μm and (c) Fluorescence
microscopic images of fluorescein dye encapsulated PCL NPs in membranes in high
magnification.
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(b)

(c)

Figure 8. Characterization of PCL NP embedded filter. SEM images of the cross-sections
of membranes prepared from (a) CA membrane, scale bar = 100 μm, (b) CA membrane
with PCL NPs in low magnification, scale bar = 100 μm and (c) Fluorescence
microscopic images of fluorescein dye encapsulated PCL NPs in membranes in high
magnification (cont.).
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3.9. PERMEATION OF WATER USING CA MEMBRANES WITHOUT AND
WITH PCL NPs
The measurement of water flux driven by gravity-flow through CA membrane
was illustrated in Figure. S4, which did not require any pumping equipment or any
vacuum driven setup other than gravity. The permeation water fluxes were approximately
25 and 17

.

at the end of 1 h through the CA membranes without and with PCL NPs,

respectively, and reduced to 15 and 11

.

, respectively, at the end of 8 h of operation

(Figure. 9a). These results were in agreement with previously reported values. 91-93
Although the incorporation of PCL NPs appeared to create larger in size pores in the
membrane structure (Figures 9a and 9b) that could be favorable for water to flow
through, it also increased the membrane thickness and hence the overall mass transfer
resistance to water flow quite significantly, which may explain the resultant lower
permeation fluxes. In addition, the presence of NPs occupying the pore space could also
have a similar effect by resulting in significantly narrowed passageways for water flow.
When LPS was mixed with water, the water fluxes were observed to be lowered as well
(Figure. 9b). Specifically, the LPS containing water fluxes at the end of 1 h and 8 h were
reduced to ~5.4 and ~2.5

.

.

using the original CA membrane, and ~4.2 and ~2.2

using the CA membrane embedded with PCL NPs. There could be a number of

factors contributing to this phenomenon, which were considered not within the scope of
this work but worthy of future studies. For example, the binding of LPS, being large
elongated molecules, to the surfaces of the pores and PCL NPs could significantly reduce
the pore sizes for water flow. The addition of LPS also changed the mass density of the
solution which would certainly affect the gravity-driven flow through the membrane.
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These factors can be pursued in the future in order to obtain a deeper understanding and
enable further optimization of the membrane pore structure for achieving even greater
processability of the LPS-containing solutions.

(a)

Figure 9. Water flux performance of CA and PCL impregnated CA membrane. The water
flux performance of CA membrane (open circles; ○) and CA membrane impregnated
with PCL NPs (filled, solid circles; ●) (a) in the absence of LPS and (b) in the presence
of LPS. The flow rates were measured under gravity. Error bars represent standard
deviations from three independent experiments. * and ** indicates p values of 0.03 and
0.01, respectively, representing statistically significant differences between the CA
membrane and PCL NPs in CA membrane.
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Figure 9. Water flux performance of CA and PCL impregnated CA membrane. The water
flux performance of CA membrane (open circles; ○) and CA membrane impregnated
with PCL NPs (filled, solid circles; ●) (a) in the absence of LPS and (b) in the presence
of LPS. The flow rates were measured under gravity. Error bars represent standard
deviations from three independent experiments. * and ** indicates p values of 0.03 and
0.01, respectively, representing statistically significant differences between the CA
membrane and PCL NPs in CA membrane (cont.).

3.10. CA MEMBRANES WITHOUT AND WITH PCL NPs FOR REMOVING LPS
FROM WATER
To confirm the adsorption capability of PCL NPs in a membrane form for
potential application in larger scale operations, the LPS removal efficiencies by the CA
membranes with or without PCL NPs were measured and compared. As can be seen in
Figure. 10a, the incorporation of PCL NPs in membrane significantly boosted the LPS
removal efficiency from ~48% to ~75% at the end of 1 h, and from 88% to near
completion at the end of 8 h. The specific endotoxin units (EU) removed were further
calculated and compared in Figure. 10b and Table S9, which clearly demonstrated the
superior performance of PCL NPs in the membrane as compared to its pristine powder
form. The removal efficiency per unit area was ~4.3 × 10 EU/cm2 (~2.8 × 10 EU/mg
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of PCL NPs) which was 2-fold (p<0.005) higher than that of NPs alone (Table S9). These
results indicate a promising avenue for removing LPS without the requirement of any
pumping devices or external power sources through the utilization of PCL NPs both in
powder and membrane forms.

(a)

Figure 10. The LPS removal efficiency of PCL NP embedded filters. (a) Efficacy tests of
CA membrane (open circles; ○) and CA membrane with PCL NPs (filled, solid circles;
●) for the removal of LPS from the water. 𝐶 = 270 𝐿𝑃𝑆 and PCL dose≈
1670 𝜇𝑔/𝑐𝑚 of membrane. *, ** and *** indicate p values of 0.03, 0.01 and less than
0.005 respectively, demonstrating statistically significant differences between PCL NPs
in CA membrane and CA membrane. (b) Bar plot of LPS removed (EU) / mg of PCL
NPs in powder form and also in CA membrane. The extent of error bar for PCL NPs in
CA membrane is small due to the fact that the percentage LPS removal reached ~100 %.
The difference between PCL NPs in powder and in the membrane is statistically
significant (p<0.05).
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Figure 10. The LPS removal efficiency of PCL NP embedded filters. (a) Efficacy tests of
CA membrane (open circles; ○) and CA membrane with PCL NPs (filled, solid circles;
●) for the removal of LPS from the water. 𝐶 = 270 𝐿𝑃𝑆 and PCL dose≈
1670 𝜇𝑔/𝑐𝑚 of membrane. *, ** and *** indicate p values of 0.03, 0.01 and less than
0.005 respectively, demonstrating statistically significant differences between PCL NPs
in CA membrane and CA membrane. (b) Bar plot of LPS removed (EU) / mg of PCL
NPs in powder form and also in CA membrane. The extent of error bar for PCL NPs in
CA membrane is small due to the fact that the percentage LPS removal reached ~100 %.
The difference between PCL NPs in powder and in the membrane is statistically
significant (p<0.05) (cont.).

3.11. PRODUCT COMPARISON
PCL NPs and PCL NP retaining membranes were compared against five
commercially available endotoxin removal products (Figure. 11 and Table I) following
the manufacturers’ instructions. A neutral pH 7.4 PBS solution containing ~2.8 × 10
EU/ml of endotoxin was loaded in the presence of each product to determine the LPS
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clearance and protein recovery. PCL NPs and membranes showed 1.25 to 30-fold higher
efficiency than other commercially available products.

Figure 11. Endotoxin removal product comparison. PCL NPs show higher LPS binding
capacity as well as higher protein recovery than five commercially available endotoxin
removal products.

Table 1. Comparison of PCL NPs and the NP containing membrane versus four
commercially available endotoxin removal products.
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4. DISCUSSION

Relatively few polymers have been investigated for their potential to be
synthesized into NP adsorbents for LPS removal. On a preparative scale, an important
indicator of desirable properties from such NP adsorbents is the adsorption capacity per
unit mass. In this work, the equilibrium adsorption capacity of PCL NPs in powder form
and in the membrane was found to be more than 2.8 × 10 𝐸𝑈/𝑚𝑔 of NPs as shown in
Tables S2-S6 and Table S9. Previously, polymyxin B cross-linked cellulose porous
microspheres of ~150 μm in diameter have been shown to have a maximum adsorption
capacity of 3.6 × 10 𝐸𝑈/𝑚𝑔.77 These porous beads, despite offering a high internal
surface area for LPS adsorption, also present hindered intraparticle mass transport within
their porous structure so that their use in a membrane or in a chromatographic column
requires a large pressure drop.94 One way to circumvent this challenging issue of high
pressure drop associated with high internal adsorption capacity is to use a nonporous
solid adsorbent particle that has sufficient capacity on the exterior surface to achieve high
adsorption efficiency at short residence time and under low pressure drop. As a type of
such desirable adsorbent particles, PCL NPs of ~780 nm in diameter have a BET specific
area of ≈ 6.5 𝑚 /𝑔 that provides 82–98% LPS removal efficiency in water and PBS.
These data are comparable to other previously reported processes 46,77,79 and indicative of
the potential of PCL NPs to fill the gap as a suitable adsorbent for LPS removal.
The extent of LPS removal was found in previous studies to depend on the
characteristics of the buffer solution, including salt concentration and pH. Increasing the
ionic strength was found to enhance the LPS adsorption on Q-sepharose gel column. 67
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The LPS adsorption levels were 10 and 10 EU/ml in 10 and 50 mM PBS,
respectively.67 Similar high LPS binding properties were shown by hydroxyapatite,
polystyrene, Dowex 1-X2, activated charcoal, phenyland octyl-sepharose in presence of a
high concentration of ammonium sulfate salts.69 Our PCL NPs were found to remove
more than 10 EU/ml using 150 mM PBS containing 137 mM NaCl (Figures 2 –5),
which represents an adsorption level almost 1000 fold higher than those of the previously
published results. The effects of pH (protons) are also contingent on the electrostatic
properties of the adsorbents.68,95 In this work, the adsorption driving forces between the
generally hydrophobic PCL NPs (adsorbent) and LPS (adsorbate) are dominated by the
van der Waals interactions and hydrophobic binding, which are further enhanced by
increasing pH that weakens the repulsion between the adsorbent and the adsorbate as
both possess partially negatively charged moieties. The enhancement in LPS binding to
hydrophobic PCL surface can be attributed to the weakening of the shielding effect
common with water molecules which cannot wet the hydrophobic surface and instead
form highly ordered shell-like structure or shield around the hydrophobic surface due to
its inability to form hydrogen bonds in all directions, thus enhancing the interaction
between two hydrophobic surfaces (LPS and PCL).66-71
Combinedly, our results suggest that the highly effective LPS separation could be
due to synergistic van der Waals and hydrophobic-hydrophobic interactions driving the
selective LPS binding with the PCL NP surface. The hydrophobic interaction of LPS
lipid tails with PCL NPs allows recruitment and assembly of LPS molecules on the NP
surface. This process is synergized further due to the hydration of LPS polar head groups
by the partially positively charged hydrogen ions of water. When LPS and PCL NPs are
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introduced to a protein solution, water molecules may rearrange by forming hydrogen
bonds surrounding the LPS-PCL nanoparticle complex shell, thus effectively secluding
the access of proteins to the particles. Because of this unstable nature of partial hydrogen
ion plane surrounding the LPS-PCL NP complexes as well as individual observations, a
wide variation in standard deviation was measured in water. In contrast, the presence of
lyotropic salts like sodium chloride in PBS interacts strongly with these water molecules
thus leaving less water available for the shielding effect to take place.
The effect of different buffers at variable pH’s and constant ionic strength was
investigated (Figure. 6). Isoelectric point for LPS is at pH 2, hence LPS is negatively
charged at pH > 2.80 PCL NPs, on the other hand, has an isoelectric point at around pH 4
96

and thus are positively charged at pH< 4 and negatively charged for pHs> 4. At pH 2.8

(acetic acid buffer), LPS would be negatively charged and PCL will have a positive
charge, hence in addition to strong hydrophobic and van der Waals interaction, ionic
interaction contributes towards LPS binding on PCL and thus a high LPS removal of ~90
% was observed. The presence of acetate ion (CH3COO-) which is a lyotrope also helps
in enhancing or promoting the hydrophobic interaction even further. As the buffer pH
increases greater than 4, both PCL NPs and LPS exhibit negative charges due to their
carbonyl and phosphate groups respectively. Based on these results, it can be concluded
that in case of phosphate buffer (pH 5.8-8) the repulsion between LPS and PCL NPs
dominates the hydrophobic and van der Waals interactions and therefore results in
reasonably low LPS removal efficiency varying between 30-75%. For sodium
bicarbonate buffer (pH 9.6), there was a sharp rise in LPS removal efficiency up to
~90%, indicating that the hydrophobic and van der Waals interaction dominates the
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repulsion action between PCL and LPS molecules at high pH. One major advantage of
the biocompatible PCL particles is that they can be reused for LPS binding quite
effectively without a major loss in binding efficiency (Figure. 7).
The LPS removal efficiency is further increased when PCL NPs were
incorporated into a CA membrane, resulting in an adsorptive membrane that delivers a
productivity flowrate of up to 25

.

(Figure. 9a and 9b).97 The porous CA membrane

structure (Figure. 8a) has a small thickness (Table S6) and a favorable pore size
distribution to not require high pressure drops for water flow across the membrane.
Further insight in this respect can be obtained from an analogy using the HagenPoiseuille equation,

P 

 Lq
2 a 2

 7

where the pressure difference (∆𝑃) can be related to 𝜇 = 𝑣𝑖𝑠𝑐𝑜𝑡𝑦 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 = 8.9 ×
10 𝑃𝑎. 𝑠, 𝐿 = membrane thickness = 130 × 10 𝑚, 𝑞 = 𝑣𝑜𝑙𝑢𝑚𝑒𝑡𝑟𝑖𝑐 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 =
25

.

= 6.9 × 10 𝑚/𝑠 and 𝑎 = 𝑝𝑜𝑟𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 = 0.17 × 10 𝑚. The resultant ∆𝑃

is equivalent to a low value of 63 Pa, which confirms the unnecessity of any pumping
device for the solution to pass through the membrane to allow the adsorption removal of
LPS to take place on the inside by the PCL NPs.
It is worth mentioning here that one direction for future study is to optimize the
membrane pore structure to achieve higher productivity flowrates without sacrificing the
loading and adsorption capability of PCL NPs. Some possibilities98 in this regard could
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result from using more branched cellulose polymers, additives or cross-linkers, and
templated casting surface. In addition, a very preliminary cost analysis was performed
(Table I) to get an idea of the costs associated with manufacturing the PCL NP embedded
CA membrane. The result was acceptably less than a dollar per cm 2 . However, more
extensive and rigorous analysis is needed when an actual process is being designed or in
operation, which needs to take into account labor, utilities, storage, and other process
variables including potentially pumping devices.

5. CONCLUSION

In this study, we report first the synthesis of polymeric PCL NPs by employing a
solvent evaporation method and then the performances of PCL NPs for the adsorption
and removal of LPS. It was found that PCL NPs in powder form removed around 88% of
LPS from the water sample. The presence of salts via the addition of PBS increased the
LPS removal efficiency further up to 100% by PCL NPs, while maintaining 100% protein
recovery from solutions. This high removal efficiency of LPS from water and PBS
attributed to strong hydrophobic and van der Waals interaction. Buffers of variable pH
play a very important role in determining the LPS binding on PCL. Acidic (pH 2.8) and
alkaline (pH 9.6) buffers give ~ 90% LPS removal whereas intermediate pHs from 5.8 to
8 give reasonably lower % LPS removal between 30-75%. The adsorption efficiency
reached almost 100% when PCL NPs were incorporated into the CA membrane where
the water flow through the porous structure was directly by gravity without the
requirement of any pumping devices. The biocompatible PCL NPs can be reused by
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desorbing majority of adsorbed LPS using 0.2 N NaOH solution. A preliminary cost
analysis showed that the manufacturing cost of the PCL NP embedded CA membrane is
quite affordable. These findings coupled with PCL NP’s known biodegradability support
the potential of hybrid NP-membrane system to be used in large-scale operations that
remove LPS efficiently and reduce the downstream process costs in biotechnological
industries.
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SUPPLEMENTARY INFORMATION

Figure S1. A standard curve to determine the optimum mass ratio of BODIPY : LPS
interaction at different concentrations of LPS. BODIPY concentration was 262.11µg/ml.
Addition of LPS to BODIPY results in quenching due to binding of LPS to BODIPY
sites. The binding saturates at 150 µg/ml endotoxin concentration. The optimum ratio of
BOD: LPS was found to be 1.74.
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Figure S2. To confirm the linear correlation of the BODIPY assay standard curve for LPS
detection (Figure S1) within the range of 0-50 g/ml, the calibration curve was
regenerated independently over the range of interest. (a) The BODIPY assay standard
curve indeed shows a linear relationship at this low LPS concentration range. We further
tested this new standard curve to calculate % LPS removal using LPS feed concentrations
between 0-50 g/ml. (b) The % LPS removal calculated using the correlation shown in
(a). (c) The % LPS removal (solid circles) was compared with the values generated using
Figure S1(open circles) as shown in Figure 2 (b) in the main texts. The values from two
independently generated standard curves were found to be evenly distributed and fit
within the error range which ensured the preparation of the calibration standards.
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Figure S3. Protein standard curves of BSA and Trastuzumab (TTZ; Genentech) in water
and PBS (pH 7.4) and Fibrinogen and Human hemoglobin in PBS (pH 7.4) were used to
measure protein concentrations. R2 represents the regression value.
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Table S1. Buffer recipes of different pHs to study the effects of pH on LPS removal.
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Figure S4. Experimental set up of a custom-made PVC column to sandwich CA
membrane without and with PCL NPs in between two flow pipes. A piece of membrane
was screw tightened between two flow pipes (top and bottom). Water and LPS containing
water was fed on the top PVC pipe and let it flow by gravity. The permeability of
membrane and % LPS removal were assessed using this set-up.

Table S2. The LPS binding capacity, endotoxin unit (EU) removed by per surface area
and per milligram of PCL NPs in water. 1 EU≈ 0.1 – 0.2 𝑛𝑔 of LPS.
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Table S3. The LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying
BSA concentrations in PBS (pH 7.4) when treated with a fixed concentration of LPS (150
g/ml  1.5 × 10 EU/ml). 1 EU≈ 0.1 – 0.2 𝑛𝑔 of LPS.

Table S4. LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying
Trastuzumab concentrations in PBS (pH 7.4) when treated with a fixed concentration of
LPS (150 g/ml  1.5 × 10 EU/ml).
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Table S5. LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying
Fibrinogen concentrations in PBS (pH 7.4) when treated with a fixed concentration of
LPS (150 g/ml  1.5 × 10 EU/ml).

Table S6. LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying Human
hemoglobin concentrations in PBS (pH 7.4) when treated with a fixed concentration of
LPS (150 g/ml  1.5 × 10 EU/ml).
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Table S7. Comparison of adsorption isotherms of LPS removal with literature values.
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(a)

(b)

Figure S5. Zeta potential and LPS removal efficiency of poly-l-lysine (PLL) coated PCL
NPs. (a) The surface zeta potential of positively charged PLL coated PCL NPs which
confirmed the clear shift in surface charge towards (10 ± 0.3) mV from (-20 ± 5) mV of
bare PCL NPs (Figure 1(c)). (b) The PLL coated PCL NPs showed ~20 and 80%
reduction in % LPS removal in water and PBS, respectively compared to bare PCL NPs
indicating the cationic charges on the surface of PCL NPs decreased the interaction of
LPS with the NP surface.
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(a)

(b)

Figure S6. Surface SEM morphology of CA membrane (a) without and (b) with PCL
NPs.

Table S8. Calculations of CA membrane thickness and pore size with and without PCL
NPs.

Table S9. Detailed calculations of EU removed by PCL NPs impregnated in CA
membrane.
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ABSTRACT

Endotoxin removal from therapeutic solutions is a challenging task for the
biopharmaceutical industries. Currently, approximately one- third of all therapeutics are
produced from biological sources like Escherichia coli and Salmonella. In addition to the
useful bio therapeutics these E. coli cells also release endotoxins in the surrounding
media thus contaminating the life-saving therapeutics. Hence, these therapeutic products
need to be thoroughly purified before being used for any parenteral applications. It was
demonstrated that biocompatible polymeric PCL NPs (𝑑 ~ 800 𝑛𝑚) were effective in
removing endotoxins from aqueous solutions with a removal efficiency ~ 98 % in
phosphate buffer saline (PBS) and protein recovery of ~ 100 %. The goal of this work
was to test the validity of the hypothesis that synergistic combination of van der Waals
and hydrophobic interactions were responsible for endotoxin binding on
polycaprolactone (PCL) nanoparticle’s (NPs) surface. This hypothesis was tested by
evaluating endotoxin removal efficiency of a material which shows surface
hydrophobicity similar to that of PCL NPs. Polystyrene (PS) nanoparticles,~ 800 𝑛𝑚,
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with surface properties similar to PCL NPs were used as a control to test the hypothesis.
Additionally, this work demonstrated that acidic (pH 2.8) and basic (pH 11.5)
conditions do not have a major impact on protein recovery using PCL NPs. Six
different types of proteins with molecular weights varying from 14 kDa - 341 kDa and
isoelectric points (pI) from 4.5-10.7 showed protein recovery > 92 % under extreme
operating pH. Finally, in order to increase the throughput and address the mass transfer
limitations, the PCL NPs incorporated cellulose acetate (CA) biofilter were synthesized
and applied to different protein solutions with a maximum endotoxin removal efficiency
~ 99 % and protein recovery >92 %.

1. INTRODUCTION

The source of one-third of all biotherapeutics, presently, is gram-negative bacteria
[1, 2]

for example, Escherichia coli and Salmonella. Endotoxins are the primary and most

toxic components located on the outer cell membrane of these gram-negative bacteria. [3-8]
As a result, while extracting biotherapeutics from these bacteria, endotoxins also get
tagged along. It, therefore, requires thorough purification and polishing steps before
being used for parenteral applications.[2,9-11] Endotoxin structure comprises polar
heteropolysaccharide chains that are covalently bonded to the non-polar lipid-A moiety. [38, 12]

Lipid-A tail is responsible for anchoring and providing mechanical stability to the

endotoxin molecule in the cell membrane. [3, 8, 12] Removing undesirable contaminants
like endotoxins from biologically derived therapeutic products thus is a challenging task
for biopharmaceutical engineers. Isoelectric point (pI) of endotoxin molecules is at pH 2,
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thus in most biological solutions endotoxin structure comprises a hydrophobic lipid tail
and a negatively charged phosphate group. Therefore, both ionic [7, 13-17] (ion exchange
chromatography) and hydrophobic interactions[18, 19] (hydrophobic interaction
chromatography) are widely utilized to bind and remove endotoxins from biological
solutions. Endotoxin binding mechanism on the ligand surface is dependent on the ionic
strength of the liquid media. In liquid media with low high ionic strength binding is
mainly dominated by charge based ionic interaction which weakens in presence of salt
ions. On the other hand, in conditions of higher ionic strength (PBS; 150 mM),
interactions driven by hydrophobicity and van der Waals binding are more impactful. [20]
In literature different types of interactions have been highlighted to remove
endotoxins from biological solutions. For example, bare polymeric nanoparticles and
adsorbent crystals like polycaprolactone nanoparticles (PCL NPs) [21] and allantoin[22]
(2,5-dioxo-4-imidazolidinyl urea) have shown high endotoxin removal efficiency of > 98
%. These adsorbents also provide high protein recovery of > 92 % and ~ 80 %
respectively, hence making these a viable alternative to remove endotoxins from protein
solutions. PCL NPs have been reported to utilize van der Waals and hydrophobic
interactions[21] to bind endotoxins whereas endotoxin binding on allantoin surface is
mediated by hydrogen bonding.[22] In addition to the bare particles, different types of
endotoxin-selective ligands have been grafted, immobilized or coated on the surface of
metallic or polymeric matrices to devise a viable endotoxin binding material. For
example, chitosan-iron oxide nanocomposites have also been very effective at binding
negatively charged endotoxins from various protein solutions due to their positive charge
from chitosan.[12]It provides an endotoxin removal of > 99 % and a protein recovery > 90
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%.[12] Polymyxin-B is another such ligand which finds widespread application in
endotoxin binding. Polymyxin-B coated silver nanoparticles have been shown to remove
> 97 % endotoxins from aqueous solutions.[23] These coated silver particles utilize ionic
interaction between the phosphate ion on endotoxin and cationic peptide on polymyxinB. Polymyxin-B with other ligands like polyethyleneimine (PEI), histamine and
tetracaine have been used to modify surface of polystyrene core and polyglycidyl
methacrylate shell based polymeric nanoparticles to use these as an endotoxin binding
material.[20] The modified nanoparticles have been shown to have an endotoxin removal
efficiency of around 90 % from water and salt solutions. They utilize van der Waals,
hydrophobic and ionic interactions to bind endotoxin on their surface. Additionally,
grafting of long carbon chain on nanoparticle surface to induce hydrophobicity has also
been utilized in many cases. One such system comprised of long C18 acyl chains
attached to Fe3O4/Au/Fe3O4 nanoflowers (NFs). These NFs utilize hydrophobic
interaction between the lipid-A part and C-18 chains to carry out endotoxin removal
effectively.[24]
Even though porous resins (with or without ligands) based techniques are
effective at binding and removing endotoxin from biological solutions they suffer from
various drawbacks like, high pressure drop, poor mass transfer, clogging and pore
structure damage.[25, 26] Hence, downstream purification operation with these materials is
expensive and inconvenient. Also, Polymyxin-B and histamine immobilized resins can
lead to neurotoxicity and nephrotoxicity.[3, 6-8, 27] To address these drawbacks, non-porous
and biocompatible PCL NPs (𝑑 ~ 800 𝑛𝑚) were synthesized for binding endotoxin on
their surface.[21] The present work attempts to test the validity of the hypothesis that van
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der Waals and hydrophobic interactions are responsible for endotoxin binding on the
hydrophobic surface. To test the hypothesis, a model polymer, polystyrene nanoparticles
with hydrophobic surface similar to that of PCL NPs are used as a control. In addition,
the effect of extreme pH conditions on protein recoveries has also been investigated.
Also, the paper extends the application of PCL NPs incorporated cellulose acetate (CA)
biofilter in removing endotoxins from protein solutions. The biofilter combine the
advantages of both PCL NPs and thin sheet flat filters for improved binding and flow
properties at a reduced cost with higher throughput.

2. MATERIALS AND METHODS

2.1. SYNTHESIS OF BARE PCL AND MODIFIED PCL NANOPARTICLES
Bare PCL NPs were synthesized using the solvent evaporation technique which
utilized high–speed homogenization and sonication, followed by solvent evaporation,
centrifugation to remove surfactants, and finally freeze-drying to remove water. [21, 28-32] A
preformed polycaprolactone (PCL) polymer solution in ethyl acetate at a concentration of
10 mg/ml was injected using a syringe pump to a 1% w/v polyvinyl alcohol (PVA)
solution prepared with reverse osmosis (RO) water. The mixture was homogenized by
using a homogenizer rotating at 3000 rpm while being placed in a sonication bath. Ethyl
acetate was removed by stirring the mixture at 300 rpm for two days. The obtained
particle suspension was washed five times using RO water and centrifugation for 30
minutes at 10,000 rcf. The resulting products were freeze-dried, weighed, and stored at
4ºC until further use. PCL NPs surface was coated with three different cationic ligands.
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The three ligands used were poly-L-Lysine (PLL; Sigma Aldrich), polyethylenimine
(PEI; Sigma Aldrich) and chitosan (MP Biomedicals). [33] To coat the surface of bare PCL
NPs, 10 mg of freeze dried PCL NPs were incubated with 1 ml of 50 µg/ml solution of
these ligands for 1 h. Post incubation the particle suspension was centrifuged for 30 min
at 16,000 rcf and the supernatant was separated. Subsequently, the ligand-coated
nanoparticles were washed with RO water five times and the particles freeze-dried to
obtain positively charged and modified PCL NPs.

2.2. CHARACTERIZATION OF BARE PCL AND MODIFIED PCL
NANOPARTICLES
The surface morphology, topology and geometry of PCL NPs were observed
using Hitachi S-4700 scanning electron microscope (SEM) at an accelerating voltage of
15 kV. Samples were sputter coated with Denton Au/Pd coater before being inserted into
the microscope. The average PCL NP size was measured by analyzing the SEM images
using the ImageJ software (version 1.51w). The average particle size was reported as
mean ± standard deviation (SD) based on the diameters of 200 randomly selected
particles. The hydrodynamic size and surface charge of NPs were characterized by
dynamic light scattering (DLS) and zeta potential (𝜁) measurements, respectively using
Malvern NanoZS90 Zetasizer. The hydrodynamic diameter of PCL NPs was measured at
25ºC using He-Ne Lasers at 90º scattering angle. The size distribution was obtained based
on three independent experiments utilizing 100 successive runs. Zeta potential values
were reported based on three independent experiments; each experiment utilizing 15
successive runs, and the results were reported as millivolts (mV) ± SD.
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2.3. EFFECTS OF pH ON PROTEIN RECOVERIES
BCA assay (Thermo fisher scientific) was employed to calculate the amount of
protein recovered after endotoxin was removed from the solution using polymeric
particles. Six different proteins were used in the experiments, namely, ovalbumin (pI 4.5;
Thermo fisher scientific), bovine serum albumin (BSA; pI 4.7; Thermo fisher scientific),
fibrinogen (pI 5.8; Alfa Aesar), bovine hemoglobin (pI 7.1; Sigma Aldrich), trastuzumab
(TTZ; pI 8.5; Genentech) and lysozyme (pI 10.7; Thermo fisher scientific). A suspension
of PCL NPs (1000 µg/ml) and protein (1000 µg/ml) at three different pH: acidic (pH 2.8),
pI (protein) and basic (pH 11.5) was incubated for 30 minutes under room conditions.
Subsequently, the suspension was centrifuged for 30 min at 16,000 rcf and the
supernatant was treated with BCA assay reagents to estimate the protein recoveries. This
was done by comparing absorbance values at 562 nm after and before introducing PCL
NPs using the standard curves for each protein at the given pH values (Figures. S1, S2
and S3). The different pH values are based on recipes in (Table S1).

2.4. EVALUATION OF CONJUGATION EFFICIENCY OF MODIFIED PCL
NANOPARTICLES
Conjugation efficiency of PLL, PEI and chitosan on PCL NPs was evaluated
using the ninhydrin assay.[34, 35] To begin with, 4 M sodium hydroxide buffer with pH 5.2
was prepared using glacial acetic acid, sodium hydroxide and water. Ninhydrin reagent
(125 mg/ml) was prepared using dimethyl sulfoxide (DMSO) and sodium hydroxide
buffer in 1:3 ratio. Next, to 100 µL of known standard PLL, PEI and chitosan ligand
concentrations added 100 µL of ninhydrin reagent (Sigma Aldrich) and placed the
centrifuge tubes in water bath at 80○ C for 30 minutes. Post water bath treatment cooled
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the tubes down to room temperature and added 300 µL of stabilizing agent (water).
Subsequently, poured 150 µL in triplicates from each tube into the 96 well plates and
measured the absorbance at 570 nm for each ligand concentration. To evaluate the
conjugation efficiency post incubation for each of the three cationic ligands (50 µg/ml),
centrifuged the tubes at 16,000 rcf for 30 minutes and then repeated the above steps with
100 µL of the supernatant. Percent (%) conjugation efficiency of each of the ligands can
be evaluated using the standard curves (Figure. S4).

2.5. EVALUATION OF ENDOTOXIN REMOVAL EFFICIENCY OF
PARTICLES (IN RO WATER AND PBS)
Endotoxin (Escherichia coli O111 : B4 LPS; Sigma Aldrich) removal efficiency
of bare Polycaprolactone (PCL), modified PCL and Polystyrene (PS) NPs
(Magsphere,Inc) of ~ 800 nm was evaluated using the Bodipy (BOD; Invitrogen)
fluorescence displacement assay technique.[21, 32, 36] BOD is a fluorescent dye which acts
as a lipid biomarker and quenches its fluorescence intensity (F.I) on interaction with
endotoxin.[21, 32] The evaluation of endotoxin binding on polymeric particle surface was
evaluated by indirectly calculating the amount of endotoxin present in the supernatant
after incubating the endotoxin spiked aqueous solution with known PCL NPs
concentration.[20] In these experiments, known polymer particle (PCL, modified PCL and
PS NPs) concentration of 1000 µg/ml was incubated for 30 minutes under room
conditions with known endotoxin concentration of 150 µg/ml in a centrifuge tube.
Subsequently, the suspension was centrifuged for 30 min at 16,000 rcf and the
supernatant was treated with BOD to estimate the endotoxin removal efficiency. Separate
sets of experiments were performed in both RO water (pH ~7) and phosphate buffered
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saline (PBS; 150 mM, pH ~7.4). The composition of PBS is as follows: 137 mM NaCl,
10 mM phosphate, and 2.7 mM KCl at 25C. Endotoxin removal efficiency of
polystyrene NPs was also calculated at 10X and 100X dilutions of PBS in addition to
the PBS alone to study the effect of salt ionic strength on endotoxin removal.
The F.I. of BOD was used to determine the endotoxin concentration in solution.
The F.I. measurements were carried out using a microplate reader (BioTek). Excitation
and emission wavelengths for BOD were 485/20 and 528/20 nm, respectively. RO water
was used as a negative control. The background fluorescence intensities were subtracted
to avoid any interferences. The percentage (%) endotoxin removal by polymeric NPs
from water and PBS was calculated using equation (1):

% Endotoxin removal 

where 𝐹𝐼
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represent the F.I. of BOD alone, BOD mixed

with endotoxin, and BOD mixed with supernatant of polymeric NPs and endotoxin
suspension, respectively.

2.6. SYNTHESIS OF CELLULOSE ACETATE (CA) BIOFILTER
Blank CA biofilter without any PCL NPs were prepared by a non-solvent induced
phase separation process.[21, 37, 38] A casting solution was prepared by dissolving 10 wt.%
each of CA and 5 wt.% glycerol in dimethyl sulfoxide (DMSO). For biofilter with NPs, 1
wt.% of PCL NPs was dispersed in the casting solution under vigorous stirring (1100
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rpm) at 50ºC for 1 h to allow homogenous mixing and then left overnight to allow
complete release of bubbles. The final solution was cast on a casting plate and then
immersed in RO water coagulation bath for 30 min. Finally, the water wet biofilter was
immersed in 30% glycerol (plasticizer) for 15 min, which in addition to improving the
mechanical properties also helped in dry storage of the membrane for at least 300 days
with no major loss in membrane flux and removal properties. [21, 39]

2.7. MICROSCOPY AND MICROANALYSIS
The CA biofilter with or without PCL NPs was dried using the freeze–fracture
method.[40] Samples were attached to a SEM stub and sputter coated with Denton Au/Pd
coater. The biofilter surface and cross sections were imaged using the Hitachi S-4700
SEM operated at 3 kV. The biofilter surface and cross-sectional morphology, pore size,
and thickness were analyzed using ImageJ software (version 1.51w). The average
biofilter pore size and thickness were based on 100 randomly selected pores and locations
from different images. The results were reported as average ± standard deviation (SD).
The incorporation of PCL NPs in the biofilter were further validated by magnifying the
surface and cross-section of the membrane sample under consideration.

2.8. WATER FLUX STUDIES
The flux measurements were carried out using custom-made biofilter testing
experimental set-up. The apparatus comprised of two polyvinyl chloride (PVC) pipes
attached to blocks that sandwich the biofilter between them. Each of the PVC pipes had a
diameter of 1.5 cm. The top half of the experimental set-up consisted of PVC pipe which
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was 20 cm long whereas bottom half had a PVC pipe that was 10 cm long. The biofilter
area coming in contact with the water or endotoxin spiked protein solution was 1.8 cm2.
For each experiment the feed volume (water or endotoxin spiked protein solution) was
kept constant at 20 ml and then allowed to pass through the biofilter under the influence
of gravity. For endotoxin spiked protein solution the concentration of protein was kept
constant at 1000 µg/ml and that of endotoxin was fixed at 57.4 µg/ml. The permeate
volumes were measured at 15 minute intervals for 90 minutes duration to estimate the
change in flux.
The water flux was calculated based on the following equation (2):

J

where J (

V
A t

 2

) is the water flux of the samples, V (L) is the volume of permeate collected

at specific time interval, A (m2) is the biofilter contact area and t (h) is the time.

2.9. QUANTIFICATION OF ENDOTOXIN REMOVAL USING PCL NPS IN CA
BIOFILTER
The determination of endotoxin removal by CA biofilter with or without PCL NPs
was also carried out by BOD fluorescence displacement assay technique [32, 41] in the
apparatus described above. A volume of 20 ml protein solution (1000 µg/ml) spiked with
57.4 g/ml of endotoxin was fed to the top flow pipe to flow through a sandwiched
biofilter by gravity. A fixed volume 460 µL of the endotoxin spiked protein feed and
permeate was collected every 15 minutes until 90 minutes. The samples were mixed with
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BOD (99.99 µg/ml) and the F.I. of BOD was measured using a plate reader (BioTek).
The percent (%) endotoxin removal was calculated using equation (3),

% Endotoxin removal  (1 

where 𝐹𝐼

, 𝐹𝐼

.

FI BOD ,Pr otein  FI BOD ,Pr otein , End in permeate
FI BOD ,Pr otein  FI BOD ,Pr otein , End in feed

, and 𝐹𝐼

.

)  100

 3

are the F.I.s of BOD alone,

BOD mixed with endotoxin in permeate, and BOD mixed with endotoxin in the feed
solution, respectively. Each value used here were based on triplicate measurements from
three independent experiments. The mean differences and standard deviations were also
evaluated.

3. RESULTS

3.1. SYNTHESIS OF POLYCAPROLACTONE NANOPARTICLES
The spherical PCL NPs were successfully prepared using the solvent evaporation
technique. From the SEM image (Figure. 1a) and dynamic light scattering (DLS) plot
(Figure. 1b) it is apparent that the particles were spherical and non-porous with smooth
surface. The particle size was 760 ± 345 𝑛𝑚. Zeta potential (𝜁), of PCL NPs in water
was −17 ± 4 𝑚𝑉 (Figure. 1c) suggesting that the particles were reasonably stable in
suspension form and would resist agglomeration.
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(a)

(b)

Figure 1. Characterization of PCL NPs. (a) SEM image of PCL NPs at 30,000 X
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL
NPs in water. Multiple colors indicate different independent runs.
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(c)

Figure 1. Characterization of PCL NPs. (a) SEM image of PCL NPs at 30,000 X
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL
NPs in water. Multiple colors indicate different independent runs (cont.).

3.2. EFFECT OF pH ON PROTEIN RECOVERIES
The effect of pH on protein recovery were also investigated for six different
proteins in presence of PCL NPs. Proteins used in the experiments were: ovalbumin
(M.W- 42.7 kDa; pI 4.5), bovine serum albumin (M.W- 66.5 kDa; BSA; pI 4.7),
fibrinogen (M.W- 341 kDa; pI 5.8), bovine hemoglobin (M.W- 64.5 kDa; pI 7.1),
trastuzumab (M.W- 148 kDa; TTZ; pI 8.5) and lysozyme (M.W- 14.3 kDa; pI 10.7).
Protein recovery for each samples were evaluated at three different pH conditions: pH
2.8, pH= isoelectric point (pI) and pH 11.5. In each set of experiments the proteins were
water based and a fixed concentration of 1000 µg/ml was used for proteins and PCL NPs.
At pH 2.8, all the protein samples except TTZ gave high protein recoveries > 96 %
(Figure. 2). The protein recoveries varied between 94% for TTZ to 100 % for lysozyme.
At pH 11.5, all the protein samples except lysozyme saw protein recoveries > 97 %
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(Figure. 2). The protein recoveries varied between 93% for lysozyme to 100 % for
fibrinogen and bovine hemoglobin. On performing the experiment at the pI, protein
recoveries ~ 100 % (98-100 %) were seen for all protein samples (Figure. 2). The
recipes to obtain the mentioned pH’s can be found in the supplementary information
section (Table S1).

Figure 2. The effects of pH on protein recovery using PCL NPs. The effect of pH on
protein recoveries was evaluated at three different values: pH 2.8, isoelectric point (pI)
and 11.5. Six different types of proteins with different pI’s and molecular weights were
used: Ovalbumin (M.W- 42.7 kDa; pI 4.5), Bovine Serum Albumin (BSA; M.W- 66.5
kDa; pI 4.7), Fibrinogen (Fib; M.W- 341 kDa; pI 5.8), Bovine Hemoglobin (M.W- 64.5
kDa; pI 7.1), Trastuzumab (TTZ; M.W- 148 kDa; pI 8.5) and Lysozyme (M.W- 14.3
kDa; pI 10.7) Particle and protein concentration were kept constant at 1000 g/ml.
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3.3. ENDOTOXIN REMOVAL EFFICIENCY COMPARISON FROM WATER
AND PBS USING PCL NPs AND POLYSTYRENE NPs
As stated before PCL NPs were hypothesized to utilize synergistic combination of
van der Waals and hydrophobic interactions to bind and remove endotoxin from
biological solutions effectively. Similar to PCL NPs, PS NPs also possess a hydrophobic
surface and show binding affinity towards endotoxin, but not as high as PCL NPs.
Endotoxin binding efficiency of PS NPs (𝑑 ~ 800 𝑛𝑚) was investigated in water and
PBS at different dilutions. PS NPs (𝑑 ~ 800 𝑛𝑚) and endotoxin concentrations were
fixed at 1000 µg/ml and 150 µg/ml (1.5 × 10 EU/ml). The endotoxin binding
experiments were carried out in RO water, PBS and PBS at different dilutions (10X and
100X). PS NPs endotoxin removal efficiency was ~ 31 % (4.6 × 10 EU/ml) from water
which increased to ~ 75 % (1.1 × 10 EU/ml) in presence of PBS (Figures. 3 and S5;
Table S2). On diluting PBS to 10X and 100X the endotoxin binding efficiency reduced to
45 % (6.7 × 10 EU/ml) and 35 % (5.2 × 10 EU/ml) respectively (Figures. 3 and S5;
Table S2).

3.4. CONJUGATION EFFICIENCY OF CATIONIC LIGAND ON PCL NPs
SURFACE
Bare PCL NPs were coated with cationic ligands to modify the surface of the PCL
NPs. In these experiments three different cationic ligands were used to coat the PCL
surface. Poly-L-Lysine (PLL), polyethylenimine (PEI) and chitosan solutions (50 µg/ml)
were incubated with 10 mg PCL NPs. Conjugation efficiency for each ligand was
evaluated using the ninhydrin assay.
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Figure 3. Comparison of endotoxin removal and binding efficiency of bare PCL NPs with
Polystyrene NPs in water and PBS. % endotoxin removal efficiency comparison of PCL
NPs (𝑑 ~ 800 𝑛𝑚) with Polystyrene NPs (𝑑 ~ 800 𝑛𝑚) in RO water and PBS at
different dilutions. Particle concentration was maintained constant at 1000 g/ml and
endotoxin concentration at 150 g/ml. * indicates the p-value < 0.1 showing a statistically
significant difference between % endotoxin removal in water and PBS.

The % conjugation efficiency for PLL, PEI and chitosan ligands was 70 %, 60 %
and 71 % respectively (Figure. 4a). Subsequently, the zeta potential of modified PCL NPs
was measured. PLL, PEI and chitosan coated PCL NPs showed a zeta potential value
of 8 ± 4 𝑚𝑉, 12.6 ± 3 𝑚𝑉 and 1.4 ± 2 𝑚𝑉 respectively (Figures. 4b, 4c and 4d). The
change in zeta potential values of PCL NPs (−17 ± 4 𝑚𝑉) post incubation with the
cationic ligands indicated successful coating of the PCL surface with the desired cationic
ligand.
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(a)

(b)

Figure 4. % Conjugation efficiency and zeta potential of PLL, PEI and chitosan ligands
coated PCL NPs. (a) PCL NPs were coated with cationic ligands like, PLL, PEI and
chitosan by incubating 10 mg of particles with 1 ml of 50 g/ml ligand solution for 1
hour. Conjugation efficiency of the ligands was evaluated using the ninhydrin assay. (b)
Zeta potential of PLL coated PCL NPs. (c) Zeta potential of PEI coated PCL NPs. (d)
Zeta potential of chitosan coated PCL NPs. Different colors indicate independent runs.
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(c)

(d)

Figure 4. % Conjugation efficiency and zeta potential of PLL, PEI and chitosan ligands
coated PCL NPs. (a) PCL NPs were coated with cationic ligands like, PLL, PEI and
chitosan by incubating 10 mg of particles with 1 ml of 50 g/ml ligand solution for 1
hour. Conjugation efficiency of the ligands was evaluated using the ninhydrin assay. (b)
Zeta potential of PLL coated PCL NPs. (c) Zeta potential of PEI coated PCL NPs. (d)
Zeta potential of chitosan coated PCL NPs. Different colors indicate independent runs
(cont.).
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3.5. ENDOTOXIN REMOVAL EFFICIENCY COMPARISON FROM WATER
AND PBS USING PCL NPs AND CATIONIC LIGAND MODIFIED PCL NPs
Endotoxin removal performance of cationic ligand modified PCL NPs was
investigated from water and PBS (pH 7.4). For these experiments the polymer particle
and endotoxin concentrations were maintained constant at 1000 µg/ml and 150 µg/ml
(1.5 × 10 EU/ml). The endotoxin removal efficiency varied from 10 - 32 % (1.5 ×
10 − 4.8 × 10 EU/ml) for cationic ligand modified PCL NPs in water (Figures. 5 and
S6; Table S3). Under the same conditions PCL NPs showed an endotoxin removal
efficiency of ~ 82 % (1.2 × 10 EU/ml) which was much higher than cationic ligand
coated particles (Figures. 5 and S6; Table S3). In presence of PBS endotoxin binding
due to ionic interaction further weakened (Figures. 5 and S6; Table S4) as the removal
performance of cationic ligand coated particles dropped further to 8 - 10 % (1.2 ×
10 − 1.4 × 10 EU/ml). On comparison, PCL NPs (Figures. 5 and S6; Table S4) saw
an upward increasing trend with a removal efficiency of ~ 98 % ( ~1.4 × 10 EU/ml)
in PBS solution.

3.6. ENDOTOXIN REMOVAL FROM PROTEIN SAMPLES USING PCL NPs
INCORPORATED CA BIOFILTER
PCL NPs showed good endotoxin binding efficiency from water, phosphate
buffer saline (PBS) and therapeutics. Thus, in this work cellulose acetate (CA) biofilter
with PCL NPs incorporated in the matrix were used to bind and remove endotoxin from
various protein solutions. The biofilter were prepared using the non-solvent induced
phase separation technique (NIPS).
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Figure 5. Comparison of endotoxin removal and binding efficiency of bare PCL NPs with
cationic ligand modified PCL NPs in RO water and PBS. % endotoxin removal efficiency
comparison of PCL NPs , PLL, PEI and chitosan coated PCL NPs in RO water and PBS.
Particle concentration was maintained constant at 1000 g/ml and endotoxin
concentration at 150 g/ml. ***, ** and * indicates the p-value < 0.01, < 0.05 and < 0.1
showing a statistically significant difference between % endotoxin removal in water and
PBS.
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Figures 6a and 6b represent the SEM image of CA biofilter and PCL incorporated
CA biofilter. From the images it can be seen that the surface pore size of CA and PCL
incorporated CA biofilter is 0.37 ± 0.13 m and 0.40 ± 0.12 m respectively. CA and
PCL incorporated CA biofilter had a thickness of 117 ± 4 m and 120 ± 3 m
respectively. Presence of PCL NPs in the biofilter can be confirmed from Figure. 6b.

(a)

Figure 6. Surface and cross-section morphology of biofilter. The SEM images represent
the surface and cross-section morphology of two different types of biofilter: (a). Surface
and cross-sectional morphology of cellulose acetate (CA) biofilter. Pore size and
thickness of the biofilter were estimated based on 100 random measurements and is 0.37
± 0.13 m and 117 ± 4 m respectively. (b). Surface and cross-sectional morphology of
PCL NPs incorporated CA biofilter. Pore size and thickness of the biofilter were
estimated based on 100 random measurements and is 0.40 ± 0.12 m and 120 ± 3 m
respectively.

(b)

126

Figure 6. Surface and cross-section morphology of biofilter. The SEM images represent
the surface and cross-section morphology of two different types of biofilter: (a). Surface
and cross-sectional morphology of cellulose acetate (CA) biofilter. Pore size and
thickness of the biofilter were estimated based on 100 random measurements and is 0.37
± 0.13 m and 117 ± 4 m respectively. (b). Surface and cross-sectional morphology of
PCL NPs incorporated CA biofilter. Pore size and thickness of the biofilter were
estimated based on 100 random measurements and is 0.40 ± 0.12 m and 120 ± 3 m
respectively (cont.).

Water flux experiments with gravity as the driving force were carried out for both
biofilter, with and without PCL NPs. As shown in Figure. 7a the pure water flux of CA
(open circles; dotted lines) and PCL NPs incorporated CA biofilter (solid circles; solid
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lines) was approximately 200 and 150
reduced to 12 and 26

.

.

to begin with at the end of 15 minutes which

, respectively, at the end of 90 minutes of operation. When

water flux measurements of protein samples spiked with endotoxins were carried out a
drop in water flux was observed with both CA (dotted lines) and PCL incorporated CA
biofilter (solid lines). Average water flux at the end of 15 minutes was 90

.

for BSA

(●), ovalbumin (■), bovine hemoglobin (▲), lysozyme (○) and trastuzumab (□) proteins
when passed though the CA biofilter (Figure. 7b). The water flux value dropped to 60
.

at the end of 90 minutes. On the other hand for PCL NPs incorporated CA biofilter

the average water flux at the end of 15 minutes was 41
to 15

.

.

(Figure. 7b) which dropped

at the end of 90 minutes.

The drop in pure water, protein and endotoxin spiked water flux in biofilter with
PCL NPs can be attributed to the resistance offered by PCL NPs incorporated within the
matrix of the filter thus slowing down the flow. Also, resistance offered by endotoxin
micelles (elongated structure) attached to the PCL surface within the membranes could be
another possible reason for the drop in flux. In terms of endotoxin removal from proteins,
we noticed a reasonably high endotoxin removal capability of CA biofilter with PCL
NPs. During the experiment five different proteins were considered namely, bovine
serum albumin (BSA), ovalbumin, bovine hemoglobin, trastuzumab (TTZ) and
lysozyme. The average maximum endotoxin removal efficiency varied from 95 % (5.5 ×
10 EU/ml) for TTZ to 99% (5.7 × 10 EU/ml) for ovalbumin at the end of 15 minutes
(Figure. 8a and S8).
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(a)

(b)

Figure 7. Water flux though CA and PCL incorporated CA biofilter. (a)Water flux plot
for 90 minute duration using CA (open circles, ○; dotted line) and PCL incorporated CA
biofilter (filled, solid circles, ●; solid line). * and ** indicates p values of < 0.1 and <
0.05, respectively, representing statistically significant differences between the water flux
of CA biofilter and PCL NPs incorporated CA biofilter. (b) Water flux for Bovine Serum
Albumin (BSA,●), Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme (○) and
Trastuzumab (TTZ, □) spiked endotoxin solution in water though CA (dotted lines) and
PCL incorporated CA biofilter (solid lines). Protein and endotoxin concentration during
the experiments were kept constant at 1000 g/ml and 57.4 g/ml. CA (open shape;
dotted line) and PCL incorporated CA biofilter (Solid shape; solid line).

At the end of 90 minutes the average removal efficiency values varied from 75 %
(4.3 × 10 EU/ml) for TTZ to 92% (5.3 × 10 EU/ml) for BSA (Figure. 8a and S8). In
terms of protein recovery, the values varied from 92 % for ovalbumin to 100 % for BSA
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and TTZ at the end of 15 minutes (Figure. 8b). At the end of 90 minutes duration the
recovery values varied between 98 and 100 % for all proteins under consideration
(Figure. 8b). The high recovery values suggest that there is minimal non-specific binding
between the protein and the PCL NPs located in the CA biofilter. For blank CA biofilter
without PCL NPs, at the end of 15 minutes the endotoxin removal values were low and
varied between 6% (3.4 × 10 EU/ml) and 30 % (1.7 × 10 EU/ml) (Figure. 8a and
S8). After 90 minutes, the endotoxin removal varied between 0 and 25 % (1.4 × 10
EU/ml) (Figure. 8a and S8). The protein recoveries were >96 % during the whole
duration.

(a)

Figure 8. The endotoxin removal efficiency and protein recovery of different proteins
using CA and PCL incorporated CA biofilter. (a) Endotoxin removal efficiency from
Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme
(○) and Trastuzumab (TTZ, □) spiked endotoxin solution in water using CA (dotted
lines) and PCL incorporated CA biofilter (solid lines). Protein and endotoxin
concentration during the experiments were kept constant at 1000 g/ml and 57.4 g/ml.
(b) Protein recovery for Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine
Hemoglobin (▲), Lysozyme (○) and Trastuzumab (TTZ, □) spiked endotoxin solution in
water using CA and PCL incorporated CA biofilter. Protein concentration during the
experiments were kept constant at 1000 g/ml.
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(b)

Figure 8. The endotoxin removal efficiency and protein recovery of different proteins
using CA and PCL incorporated CA biofilter. (a) Endotoxin removal efficiency from
Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme
(○) and Trastuzumab (TTZ, □) spiked endotoxin solution in water using CA (dotted
lines) and PCL incorporated CA biofilter (solid lines). Protein and endotoxin
concentration during the experiments were kept constant at 1000 g/ml and 57.4 g/ml.
(b) Protein recovery for Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine
Hemoglobin (▲), Lysozyme (○) and Trastuzumab (TTZ, □) spiked endotoxin solution in
water using CA and PCL incorporated CA biofilter. Protein concentration during the
experiments were kept constant at 1000 g/ml (cont.).

4. DISCUSSION

In this work, bare PCL NPs (~ 800 nm) were synthesized using the solvent
evaporation technique.[21] PCL NPs were effective in binding endotoxins from biological
solutions thus decontaminating the solution for parenteral application. To begin with, the
effect of different pH conditions on protein recovery using PCL NPs was investigated.
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For the experiments, three types of pH conditions were considered: pH 2.8 (acidic), pH =
pI (isoelectric point of protein) and pH 11.5 (basic). Isoelectric points of PCL used in the
experiments was at pH 4 and for that of endotoxin was at pH 2. [3, 8, 42] Thus, at any pH <
4, PCL would be positively charged and negatively charged at any pH > 4. Similarly, at
any pH < 2, endotoxins would be positively charged and negatively charged at any pH >
2. Isoelectric points for proteins investigated are: Ovalbumin (pI 4.5), BSA (pI 4.7),
fibrinogen (pI 5.8), bovine hemoglobin (pI 7.1), TTZ (pI 8.5) and lysozyme (pI 10.7). At
pH 2.8, all the proteins and PCL NPs surface would possess a positive charge and
endotoxin would be negatively charged. Protein recovery varied between 93 and 100
%.Van der Waals, hydrophobic and ionic interaction would be responsible for endotoxin
binding on PCL surface. PCL and proteins have same type of charges thus ionic
interaction would not cause any protein binding on PCL surface. Hence, the loss of
protein would be due to protein binding on endotoxin surface due to ionic, affinity and
hydrophobic interaction.[3, 8, 43] Subsequently, the protein laden endotoxin binds to the
PCL surface. Also, possibility of interaction between the PCL surface and proteins cannot
be neglected. In the past, lysozyme and hemoglobin have been reported to show strong
interaction with endotoxin thus corroborating the possibility of interaction between
proteins and endotoxins.[3, 8, 43] At isoelectric point, the surface of proteins are neutral,
both endotoxins and PCL NPs possess a negative charge due to their phosphate and
carbonyl groups respectively. Protein recovery varied between 98 and 100 % thus
indicating almost no interaction either between the protein and the PCL NPs or the
protein and the endotoxin. At pH 11.5, the surface of proteins, PCL NPs and endotoxins
possess a negative charge respectively. Protein recovery varies between 94 and 100 %.
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Due to similar charges on all the surfaces, ionic interaction would not contribute towards
any loss in protein after endotoxin removal. Hence, the loss in protein would be due to
affinity, van der Waals and hydrophobic interaction between PCL surface and proteins or
endotoxin and proteins.[3, 8, 43] To sum up, pH does play a role in protein recovery but in
almost all cases the protein recovery was > 93 % which is considered reasonably high.
Further, PCL NPs binding experiments were carried out by suspending PCL NPs
in the endotoxin spiked solution and then centrifuged to separate out the endotoxin laden
PCL NPs from the solution. From literature, it has been suggested that the synergistic
combination of van der Waals and hydrophobic interaction are driving the binding of
endotoxin on PCL NPs surface.[21]
The aim of this paper was to test the validity of the hypothesis. To begin with
polystyrene nanoparticles (PS NPs) of 𝑑 ~ 800 𝑛𝑚 with hydrophobic nature similar to
that of PCL NPs were taken as a control. Subsequently, the endotoxin binding
experiments were carried out to evaluate PS NPs endotoxin removal efficiency. PS NPs
had an endotoxin removal efficiency of ~ 31 % (4.6 × 10 EU/ml) in water (Figures. 3
and S5; Table S2). The binding efficiency increased to 75 % (1.1 × 10 EU/ml) in PBS
(Figures. 3 and S5; Table S2). Unlike PCL NPs, PS NPs endotoxin binding performance
was not very impressive. These results suggests that endotoxin binding on the surface of
PCL NPs is not solely due to van der Waals and hydrophobic interaction but there are
other forces that are contributing towards the endotoxin adsorption on PCL surface and
need further investigation. Even though, van der Waals and hydrophobic forces are
contributing towards endotoxin binding but that is just a small part of large group of
forces as evident from low removal efficiency by PS’s hydrophobic surface.
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The presence of water and salt molecules also play an important role in
strengthening the binding interaction between endotoxin and PCL molecules. Endotoxin
structure comprises a negative charge due to the presence of phosphate group (PO 43-) in
its polar head chain. On the other hand, PCL NPs also possess negative charge due to the
carbonyl group (CO-) in its structure. The presence of negative charges on both the
surfaces should have induced a strong electrostatic repulsive action and thus should have
acted as a barrier and impeded the binding on endotoxin on PCL surface. However, the
presence of water and salt (NaCl) molecules result in ion hydration through H + and Na+
ions and thus stabilize the charged surfaces (endotoxin and PCL) and strengthen the
attractive binding forces between endotoxin and PCL NPs surface.[21, 44, 45]
Study was also carried out to evaluate the endotoxin binding efficiency due to
ionic interaction. This was done by coating the surface of the PCL NPs with three
different cationic ligands, PLL, PEI and chitosan to make the surface cationic. [33]
Subsequently, after coating the PCL NPs with the cationic ligands the zeta potential
(surface charge) of the particles increased from ~ -17 mV (Figure. 1c) to 8, 12.6 and 1.4
mV (Figures. 3b, 3c and 3d) confirming the surface modification. The % conjugation
efficiency of the three ligands on PCL surface varied between 60 and 70 %. (Figure. 3a).
On comparing the endotoxin removal efficiency of the bare PCL NPs with the positively
charged cationic NPs in water, it was observed that PCL NPs possessed a much higher ~
82 % (1.2 × 10 EU/ml) endotoxin removal efficiency than modified NPs with values
varying between 10 and 32 % (1.5 × 10 − 5 × 10 EU/ml) (Figures. 4 and S5; Table
S2). In presence of PBS the endotoxin binding efficiency of modified cationic NPs
reduced further to ~ 8-10 % (1.2 × 10 − 1.4 × 10 EU/ml) (Figures. 4 and S5; Table
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S3). Thus, suggesting that in case of binding due to ionic interaction taking place in
water, salt ions are used to modulate the binding capacity.[46] The role of positively
charged NPs is to bind endotoxin through its negatively charged phosphate group in
water but in presence of salt (NaCl; 137 mM) in PBS, charge shielding effect comes into
play as in addition to negatively charged endotoxin molecules, chloride ions are also
competing for the same binding site thus reducing the particle’s endotoxin binding
efficiency even further.[46-49] Even though, porous resins or particle based
chromatographic separation techniques were quite mature and effective but they suffered
from various limitations like poor mass transfer, high pressure drop and in some cases
low purification efficiency as seen in the case of polymyxin B cross-linked cellulose
microspheres.[25, 26, 50, 51] The porous microspheres ~ 150 µm in size possessed high
endotoxin binding capacity of ~ 3.6 × 10 EU/mg but suffered from poor mass transfer
and large pressure drop.[51] To address these drawbacks the non-porous particle (PCL
NPs) loaded biofilter were synthesized which combined the advantages of high binding
capacity of the particles with improved flow properties and reduced pressure drop of the
flat-sheet filter.[21, 25, 26] From literature, it has been shown that PCL NPs (~ 800 nm)
incorporated CA biofilter were effective in removing endotoxins from water. [21] Here we
applied that biofilter to protein solutions and demonstrated the effectiveness of the
biofilter in removing endotoxin from protein solutions. Non-porous PCL NPs (~ 800 nm)
with a BET specific area of ≈ 6.5 𝑚 /𝑔 are very effective in removing endotoxins from
water, biological and protein solutions.[21] Hence, on incorporating these in the biofilter
matrix the combined advantages of both the particles and filters can be utilized for cost
effective and efficient downstream purification with higher throughput. [25]
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Non-porous PCL NPs loaded biofilter used in the experiments were fed with five
types of endotoxin spiked proteins, namely, ovalbumin, BSA, bovine hemoglobin, TTZ
and lysozyme. The biofilter possessed a high maximum endotoxin removal efficiency
varying between 95 and 99 % (TTZ-ovalbumin;5.5 × 10 − 5.7 × 10 )(Figure. 8a and
S8 ).Thus suggesting that PCL NPs loaded biofilter were quite effective in providing
binding sites for removing endotoxin from protein solutions. In addition to the high
endotoxin removal efficiency the protein recovery after endotoxin removal varied
between 92 and 100 % (Figure. 8b) , thus suggesting that the majority of binding sites
within the biofilter were being utilized for endotoxin binding and most of the protein was
allowed to pass through. In comparison, CA biofilter without any PCL NPs showed low
endotoxin removal efficiency between 0 % and 30 %. Another advantage associated with
the biofilter was the flux at which the removal took place. PCL NPs loaded CA biofilter
possessed a maximum pure water flux of ~ 150
and endotoxin spiked water flux of ~ 41

.

.

(Figure. 7a) and an average protein

, thus highlighting the rapidness of the

separation (Figure. 7b). It is worth mentioning here that the CA biofilter used for the
endotoxin removal from protein solutions were gravity driven (Figure. S7) thus cutting
costs associated with pumping devices.

5. CONCLUSIONS

In this work, the goal was to test the validity of the hypothesis that endotoxin
binding on PCL NP surface was due to van der Waals and hydrophobic interaction
occurring between lipid-A tail of endotoxins and hydrophobic surface of PCL. This was
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evaluated by taking polystyrene nanoparticles, which have similar hydrophobic nature as
polycaprolactone nanoparticles used as control. Subsequently, PS NPs did not show as
high endotoxin removal (31%-75 %) efficiency as PCL NPs thus suggesting that in case
of PCL NPs there were attractive forces other than van der Waals and hydrophobic
interaction that resulted in high endotoxin binding efficiency and need further
investigation. Further, the effect of pH on protein recovery for PCL NPs were also
evaluated. Six different types of proteins with molecular weights varying from 14 kDa
- 341 kDa and isoelectric points (pI) from 4.5- 10.7 were selected. pH values of 2.8,
isoelectric point of protein and 11.5 were selected for the experiments and it was
observed that protein recovery irrespective of conditions were > 93 %, which is
reasonably high. Thus suggesting that pH does not have a major effect on protein
recovery when using PCL NPs. It has also been shown that PCL NPs incorporated CA
biofilter are effective in removing endotoxins from various protein solutions with
improved flow properties and higher throughput. The maximum endotoxin removal
efficiency was ~ 99 % and a protein recovery > 92 % thus indicating that majority of
endotoxin binding sites within the biofilter were being utilized for endotoxin binding and
very less amount of protein was getting lost during the purification operation.
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SUPPLEMENTARY INFORMATION

Table S1. Buffer recipes of different pHs to study the effects of pH on protein recovery.
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Table S1. Buffer recipes of different pHs to study the effects of pH on
protein recovery (cont.).
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Figure S1. Protein standard curves of Ovalbumin, Bovine Serum Albumin (BSA), Fibrinogen,
Bovine Hemoglobin, Trastuzumab (TTZ; Genentech) and Lysozyme at isoelectric points (pI)
and were used to measure protein concentrations. R2 represents the regression value.
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Figure S2. Protein standard curves of Ovalbumin, Bovine Serum Albumin (BSA),
Fibrinogen, Bovine Hemoglobin, Trastuzumab (TTZ; Genentech) and Lysozyme at pH
2.8 and were used to measure protein concentrations. R 2 represents the regression value.
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Figure S3. Protein standard curves of Ovalbumin, Bovine Serum Albumin (BSA),
Fibrinogen, Bovine Hemoglobin, Trastuzumab (TTZ; Genentech) and Lysozyme at pH
11.5 and were used to measure protein concentrations. R 2 represents the regression value.
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Figure S4. Poly-L-Lysine (PLL), Polyethylenimine (PEI) and chitosan standard curves
for conjugation efficiency calculation using ninhydrin assay. The curves were used to
measure the ligand concentrations. R2 represents the regression value.
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Table S2. The endotoxin unit (EU) bound per ml of endotoxin-spiked solution using PCL
NPs and Polystyrene (PS) NPs in water and PBS at different dilutions. 1 EU≈
0.1 – 0.2 𝑛𝑔 of endotoxin.

Figure S5. Comparison of Endotoxin unit (EU) per ml bound to the surface of PCL NPs
with Polystyrene NPs (𝑑 ~ 800 𝑛𝑚) in water and PBS at different dilutions. EU/ml fed
was kept constant at 1.5 × 106 and particle concentration at 1000 g/ml. * indicates the pvalue < 0.1 showing a statistically significant difference between % endotoxin removal in
water and PBS.
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Table S3. The endotoxin unit (EU) bound per ml of endotoxin-spiked solution using PCL
NPs and modified PCL NPs in water. 1 EU≈ 0.1 – 0.2 𝑛𝑔 of endotoxin.

Table S4. The endotoxin unit (EU) bound per ml of endotoxin-spiked solution using PCL
NPs and modified PCL NPs in PBS. 1 EU≈ 0.1 – 0.2 𝑛𝑔 of endotoxin.
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Figure S6. Endotoxin unit (EU) per ml bound to the surface of PCL NPs, PLL, PEI and
chitosan coated PCL NPs in RO water and PBS. EU/ml fed was kept constant at 1.5 × 10 6
and particle concentration at 1000 g/ml. ***, ** and * indicates the p-value < 0.01, <
0.05 and < 0.1 showing a statistically significant difference between % endotoxin
removal in water and PBS.
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EU/ml removed

Figure S7. Custom-made membrane filtration set up made out of PVC. CA biofilter
without and with PCL NPs are sandwiched between two blocks and butterfly screws are
used to tighten the biofilter. Endotoxin spiked protein solution is fed from the top part of
the pipe and permeate is collected from the bottom half of the pipe.
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Figure S8. Endotoxin units (EU) per ml removed from Bovine Serum Albumin (BSA,●),
Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme (○) and Trastuzumab (TTZ, □)
spiked endotoxin solution in water using PCL incorporated CA biofilter (solid lines).
Protein and endotoxin concentration during the experiments were kept constant at 1000
g/ml and 57.4 g/ml (5.7 × 105 EU/ml).
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SECTION

2. CONCLUSIONS AND FUTURE WORK

2.1. CONCLUSIONS
In paper-I, we reported the synthesis of polymeric PCL NPs by employing a
solvent evaporation method, followed by the performance evaluation of PCL NPs for the
adsorption and removal of endotoxins. It was found that PCL NPs in powder form
removed around 88% of endotoxins from the water sample. The presence of salts, by
adding PBS, increased the endotoxin removal efficiency further up to 100 % while
maintaining 100% protein recovery from solutions. Such high removal efficiency of
endotoxin from water and PBS is attributed to strong hydrophobic and van der Waals
interactions. Buffers of variable pH play a very important role in determining the
endotoxin binding on PCL. Acidic (pH 2.8) and alkaline (pH 9.6) buffers give ~ 90%
endotoxin removal whereas intermediate pHs from 5.8 to 8 give reasonably lower %
endotoxin removal, that is, between 30 and 75%. The adsorption efficiency reached
almost 100% when PCL NPs were incorporated into the CA membrane where the water
flow through the porous structure was directly facilitated by gravity (not requiring any
pumping devices). The biocompatible PCL NPs can be reused by desorbing majority of
adsorbed endotoxin using 0.2 N NaOH solution. A preliminary cost analysis showed that
the manufacturing cost of the PCL NP-embedded CA membrane is quite affordable.
These findings, coupled with PCL NP’s known biodegradability, support the potential of
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hybrid NP-membrane system use in large-scale operations that remove endotoxins
efficiently and reduce the downstream process costs in biotechnological industries.
In paper-II, the goal was to test the validity of the hypothesis that endotoxin
binding on PCL NP surface was due to van der Waals and hydrophobic interaction
occurring between lipid-A tail of endotoxins and hydrophobic surface of PCL. This was
evaluated by taking polystyrene nanoparticles, which have similar hydrophobic nature as
polycaprolactone nanoparticles used as control. Subsequently, PS NPs did not show as
high endotoxin removal (31%-75 %) efficiency as PCL NPs thus suggesting that in case
of PCL NPs there were attractive forces other than van der Waals and hydrophobic
interaction that resulted in high endotoxin binding efficiency and need further
investigation. Further, the effect of pH on protein recovery for PCL NPs were also
evaluated. Six different types of proteins with molecular weights varying from 14 kDa
- 341 kDa and isoelectric points (pI) from 4.5- 10.7 were selected. pH values of 2.8,
isoelectric point of protein and 11.5 were selected for the experiments and it was
observed that protein recovery irrespective of conditions were > 93 %, which is
reasonably high. Thus suggesting that pH does not have a major effect on protein
recovery when using PCL NPs. It has also been shown that PCL NPs incorporated CA
biofilter are effective in removing endotoxins from various protein solutions with
improved flow properties and higher throughput. The maximum endotoxin removal
efficiency was ~ 99 % and a protein recovery > 92 % thus indicating that majority of
endotoxin binding sites within the biofilter were being utilized for endotoxin binding and
very less amount of protein was getting lost during the purification operation.
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2.2. FUTURE WORK
1. Expanding the application of PCL NPs loaded cellulose acetate (CA) biofilter for
removal of harmful algal toxins from lake waters. To begin with our target toxins
will be cyanotoxins, eg: anatoxin and microcystin-LR which are found quite
extensively in the lake water.
2. Exploring the possibility of using BODIPY dye, which is a lipid biomarker as a
toxin detection kit at different toxin concentrations, operating conditions and in
different solutions. BODIPY has already been shown to detect endotoxins
successfully as the structure of endotoxin molecules comprises of non-polar lipidA molecules in its tail part which is hydrophobic in nature. BODIPY, which is
fluorescent dye shows this unique property of quenching in its fluorescence
intensity when it comes in contact with lipid molecules. Thus, this quenching
property of BODIPY on coming in contact with lipid molecules was utilized to
come up with a detection kit for endotoxins. Quantification of endotoxin was
done by measuring the drop in fluorescence intensity (quenching) using the
optical microplate reader. Our future work will comprise of testing the minimum
endotoxin detection limit of BODIPY dye and also investigate the different algal
toxins which can be detected using the BODIPY dye as a biomarker.
.
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